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Introduction Clinical pharmacy and the provision of patient-focused pharmaceutical care services 
is a hospital pharmacist’s role that is slowly developing in South African private hospitals. The 
clinical pharmacist, as a valuable member of the health care team, has been shown to improve patient 
clinical outcomes. However, a number of factors hinder the progression of clinical pharmacy services 
in these hospitals. 
Aim  To promote the implementation of clinical pharmacy services in South African 
private hospitals by identifying those factors perceived by South African hospital pharmacists as 
barriers. 
Methods This observational mixed methods research study was conducted between September 
2015 and February 2016, across 52 private hospitals within the same purposively selected private 
hospital group. Pharmacy managers were recruited for semi-structured interviews during the first 
qualitative phase. The second quantitative phase consisted of the distribution of a survey 
questionnaire to 243 hospital pharmacists and pharmacy managers. 
Results The overall response rate was poor, with only 15.9% and 30.4% recorded for the 
qualitative and quantitative phases, respectively. The median percentage of time that hospital 
pharmacists spend providing a clinical service at ward level was only 17.5%, and 76.1% of 
respondents stated that availability of time was negatively impacting clinical pharmacy progression. 
All survey respondents agreed that further formal education and training was required to progress 
clinical pharmacy. Hospital management support in clinical pharmacy progression was emphasised by 
83.6% of the respondents. The lack of a recognised clinical pharmacist specialist registration category 
was identified by 70.8% of respondents as having a negative impact on clinical pharmacy progression.  
Discussion The perceived structural and behavioural barriers to clinical pharmacy service 
progression were identified as being educational requirements, human resource allocation and the 
need for hospital and governmental support. The FIP Basel Statements on the Future of Hospital 
Pharmacy require local adaptation in order to be used as a tool to monitor clinical pharmacy practice 
in hospitals in South Africa, but should be promoted to further expose the identified barriers and 
initiate corrective action.      
Conclusion The perceived barriers and steps for remedial action to educational needs, human 
resource allocation and hospital and governmental support are provided. Addressing these barriers 









The role of a hospital pharmacist has, over the past few decades, developed into that of a provider of 
quality patient care.
1
 There has been a shift away from the compounder and pharmaceutical product 
supplier role, as seen in the past, into a “drug therapy manager” and provider of pharmaceutical care 
focused on ensuring safe, effective drug therapy to enhance the patient’s quality of life.
 1
 This change 
in the role of the hospital pharmacist into one that is more clinically directed aims to meet the ever 
increasing societal need for rational medicines therapy. With such a variety and supply of medicines 
that are continuously being introduced to the healthcare market, the need to ensure they are used 
correctly and safely is of utmost importance.     
 
Clinical pharmacy, as defined by the South African Society of Clinical Pharmacy, is “an area of 
pharmacy involved with the science, practice, activity and service to develop and promote the rational 
and appropriate use of medicines and pharmaceutical care, in the interest of the patient and the 
community.”
2
 Clinical pharmacy is a pharmacy practice that aims to achieve pharmacotherapeutic 
objectives to enhance the patient’s quality of life, within a pharmaceutical care system.
3
 Through the 
provision of patient-specific pharmaceutical care, clinical pharmacists are becoming valuable 
members of the clinical healthcare team. The inclusion of the pharmacist in the clinical decision-




The level of hospital pharmacy practice varies considerably from country to country and a need to 
explore the current state of pharmacy practice globally has been identified. The Basel Statements are a 
set of 75 statements that were produced by the Hospital Pharmacy Section of the International 
Pharmaceutical Federation (FIP) in August 2008.
7
 The Statements were based on a global survey 
conducted by the FIP Hospital Pharmacy Section (HPS) to explore the current state of pharmacy 
practice and the challenges faced. The Basel Statements reflect the preferred future of hospital 
pharmacy, an ideal standard to achieve in low-, middle- and high-income countries. Clinical 
pharmacy forms one of the six aspects of hospital pharmacy practice incorporated within these 
statements which encapsulate the vision for pharmaceutical care and clinical pharmacy in the hospital 
setting.
7
 In late 2011 a revision of the Basel Statements was initiated by the FIP HPS, and a total of 65 







Clinical pharmacy services have been extensively incorporated within the private and public hospitals 
of most high-income countries.
10
 However, difficulty is experienced when establishing and sustaining 
clinical pharmacy services in the hospitals of low- and middle-income countries.
11
 There are a few 
studies that have been conducted in developing countries focused on identifying specific factors that 
are hindering the implementation of clinical pharmacy services. Penm et al. have drawn attention to 
the attitudes and opinions of hospital administrators, pharmacy directors, dispensing and clinical 
pharmacists, in both tertiary and secondary hospitals in China, towards specific external factors 
hindering clinical pharmacy development.
12 
Such a study exploring the hospital pharmacists’ 
perspectives of clinical pharmacy in private hospitals has not been conducted in South Africa. This 
type of study can be of value in identifying the level of clinical pharmacy services already present in 
private hospitals in the country, as well as highlighting the factors preventing implementation and 




In what way do private hospital pharmacists’ perspectives of clinical pharmacy and other structural 
and behavioural factors hinder clinical pharmacy service progression in South African private 
hospitals? 
 
Purpose of the Research 
 
Hospital pharmacists are becoming more clinically involved in the patient treatment process through 
participation in ward rounds, collaboration with other healthcare professionals (including medical 
practitioners) in multidisciplinary teams, as well as by providing direct patient counselling and 
medicines therapy review. As the demand for pharmaceutical care increases, the implementation and 
maintenance of sustainable clinical pharmacy models in South African private hospitals remains a 
challenge. This study aims to expose those challenges perceived by hospital pharmacy managers and 
pharmacists working within this environment, in order to identify ways in which to overcome them 




To promote the implementation of clinical pharmacy services in South African private hospitals by 







The specific objectives of the study were: 
1) To obtain the views and attitudes of selected pharmacy managers, through telephonic or face-
to-face interviews, on their perspectives on clinical pharmacy services within private hospitals 
in South Africa, and to analyse these responses by means of thematic analysis. 
 
2) To conduct an electronic survey aimed at pharmacists and pharmacy managers in a private 
hospital group in order to identify the possible factors hindering the development of clinical 
pharmacy services in South Africa. 
 
3) To make recommendations on actions that could be taken by private hospital pharmacy 
managers in order to advance the implementation of clinical pharmacy services in their 
practice settings; based on the findings of the electronic survey, telephonic and face-to-face 
interviews. 
 
4) To make recommendations to private hospital senior management on the strategic actions 
needed to advance the implementation of clinical pharmacy services in their practice settings, 






Chapter II: Literature Review 
 
Clinical pharmacy is an additional role to dispensing that the hospital pharmacist can play in 
providing pharmaceutical care services aimed at improving the patient’s clinical outcome. This role 
has been recognised and implemented to varying degrees in different countries. This chapter 
highlights the value of the clinical pharmacist within the multidisciplinary health care team, as well as 
exploring those key differences in clinical pharmacy progression within low-, middle- and high-
income countries and how these compare to the progress within South Africa. This chapter also 
establishes the need for a pharmaceutical care system as the foundation on which clinical pharmacy is 
built.     
 
2.1 Health care structure and hospital pharmacy in South Africa 
 
The population of South Africa was estimated in mid-2016 at 55.91 million people with 80.7% of the 
population self-identified as Black African.
13
 The total population is serviced by both the public and 
private health care sectors. The governmental, public sector health care structures of the country 
consist of a National Department of Health (which implement national policies, strategies and 
standard treatment guidelines), and 9 provincial health departments (which are responsible for health 
service delivery).
14
 Funding for services delivered in the public sector is based on an equitable-share 




In contrast to public sector health care, 17% of the total population is privately insured and are, by and 
large, serviced by health professionals and facilities within the private sector.
14
 Private health care is 
provided by nine hospital groups, with the majority of private hospitals in South Africa being part of 
the three largest private hospital groups. Netcare, Medi-Clinic and Life Healthcare account for 66.5% 
of all private hospitals in South Africa.
15
 There are 216 private hospitals providing 31 000 hospital 
beds to the private sector. Private health care is primarily funded by medical schemes and to a lesser 
extent out-of-pocket payments by patients. At the end of 2013 there were 87 medical schemes in 
operation with a total beneficiary count of 8.78 million.
16
 The total health care benefits paid to health 
care providers in 2013 was R112.5 billion (an average amount spent per beneficiary per annum being 
over R12 000) with 35.3% (or R39.7 billion) contributed by hospital expenditure.
16
 In total South 




General tax revenues account for 40% of the total health care finance needed to provide health care to 




funding comes from private medical schemes servicing only the insured minority.
18
 South Africa is 
planning to bridge the divide between the public and private health care sectors by implementing 
National Health Insurance, a system of universal access to health care for all.
19
 This is a complex 
process which is expected to take up to 14 years to be implemented.
14
    
 
There are 10 academic institutions across the country which offer undergraduate pharmacy courses 
leading to professional registration.
20
 All pharmacists working in the country are required to register 
with the South African Pharmacy Council (SAPC), the regulatory body for pharmacy. Currently there 
are 13 981 registered pharmacists in South Africa and of these 60.9% are female with 55% self 
identified as White, 20% as Black Africans and 20% as Indian/Asian.
20
 There are only 13 specialist 
pharmacists currently registered with the SAPC.
20
 Once qualified, pharmacists can enter the 
profession in community, institutional (public and private), academic, manufacturing, wholesale or 
consultant pharmaceutical practice areas.
21
 Apart from registered pharmacists, the pharmaceutical 
workforce also consist of pharmacist interns, community service pharmacists and pharmacist’s 
assistants (at learner basic, basic, learner post basic and post basic levels). There are currently just 
over 1000 pharmacist interns, 649 community service pharmacists and just fewer than 19 000 
pharmacist assistants registered with the SAPC.
20
 The focus of this study is on registered pharmacists 
currently employed within the private institutional sector.  
 
2.2 Clinical pharmacy in the United States and other high-income countries 
 
The American Society of Health-system Pharmacists (ASHP) conducts an annual national survey 
aimed at determining the current state of pharmacy practice and technologies used within the hospital 
setting and the role played by pharmacists.
10
 The annual survey covers six components of the 





Pedersen et al, through the 2013 ASHP national survey of pharmacy practice in hospital setting: 
prescribing and transcribing, were able to highlight the importance of pharmacy and therapeutics 
committees and the role of the hospital pharmacist within these committees.
10
 The Pharmacy and 
Therapeutics Committee (PTC) or Drug and Therapeutics Committee (DTC) is a multidisciplinary 
entity that promotes the rational use of medicines with focus on medication safety by identifying 
particular areas of inefficiency and drug use problems.
22
 In brief, “[t]he goal of the DTC is to ensure 
that patients are provided with the best possible cost-effective and quality care through determining 
what medicines will be available, at what cost, and how they will be used.”
22
 The clinical pharmacist 




his/her particular facility. These committees provide an essential service and their importance is often 
overlooked. 
 
The results of the 2013 ASHP survey also showed that, of the 1439 hospitals included in the sample, 
the most common health care professional consultations between pharmacists and prescribers were 
about dosage adjustments (98.3%) followed by drug information (93.2%), recommendations for 
antibiotic therapy (91.7%) and pharmacokinetics (91.5%).
10
 In terms of technology used in hospitals 
in the US, 92.6% of hospitals included in the survey had electronic health records (EHR) and 65.2 % 
of hospitals used computerised prescriber-order-entry (CPOE) systems with clinical decision support. 
As the survey report remarked: “Handwritten medication orders have virtually disappeared in US 
hospitals”.
10
 Barcode-assisted medication administration systems (used to verify patient identity and 
to check doses administered by nurses electronically) and electronic medication administration 
records (eMAR) were also frequently used in the majority of these hospitals.
10
 Automated dispensing 
cabinets are a decentralised medication distribution system (i.e. medication stored and electronically 
dispensed in remote areas outside of hospital pharmacy) that is used in a large majority of US 
hospitals.
23
 Other devices used include automated systems (or robots) and medication carousels, 
which are both used centrally (i.e. within the hospital or satellite pharmacy).
23
 These automated 
medication dispensing and distribution units aid in ensuring medication safety through barcode-
assisted dispensing and administration, but they also aim to free up the pharmacist from time-
consuming distributive and dispensing roles to allow for more patient-focused care and clinical work. 
 
The 2015 ASHP national survey of pharmacy practice in hospital settings, which focused on 
monitoring and patient education, showed that the majority of hospitals surveyed had pharmacists 
who were increasingly providing drug therapy management services.
24
 This survey also showed an 
increase in pharmacist and pharmacy technician involvement in patient education and medication 
reconciliation, tasks which have most often been associated with nursing staff. In terms of staffing, 
the average number of pharmacist full-time equivalents (FTE) per hospital was 11.4, with an 





Pharmacy technicians within the United States play a vital role in aiding the pharmacist in ensuring 
the safe and effective use of medicines within the hospital. The partnership between pharmacist and 
pharmacy technician is a key factor in promoting the patient-centred clinical roles of the pharmacist. 
The ASHP strongly feel that changing the way pharmacy technicians are educated, regulated and 
incorporated in pharmacy practice will advance the roles of the pharmacist.
25
 Pharmacy technicians in 




becoming more utilised in advanced, specialised clinical roles through the competence gained from 




The 2015 ASHP survey highlighted the extent to which pharmacists are exploring the clinical roles 
performed on a daily basis. A national survey of pharmacy practice and technologies used in South 
African hospitals would be of great interest, as the same clinical practice areas could be explored 
locally. We need to investigate whether processes are being used in public and private hospitals in 
South Africa that aid the hospital pharmacist in providing more clinical services to their patients; only 
then can the true value of the clinical pharmacist be discovered and entrenched. 
 
2.3 The value of the clinical pharmacist 
 
Clinical pharmacists are valuable members of the clinical health care team. Pharmacists have been 
shown to improve patient clinical outcomes through the provision of non-dispensing services.
26
 The 
provision of clinical pharmacy services has been shown to reduce hospital admissions, emergency 
department visits, drug-related hospital readmissions as well as health care related costs and length of 
stay.
4,5
 Clinical outcomes, including high blood pressure and cholesterol as well as high blood glucose 
in diabetic patients, have been managed more effectively and have shown improvements with patients 
exposed to pharmacist-provided services compared to a control group.
26 
This was also shown in a 
study conducted by Al Mazroui et al. where the provision of pharmaceutical care to Type 2 diabetes 
mellitus patients resulted in better glycaemic control and reduced cardiovascular risk scores.
27
 
Hospital pharmacists have also contributed to the improvements in the management of symptoms in 
patients with asthma through the provision of comprehensive medication counselling and education 
on the disease.
28
 Zhang et al. showed that clinical pharmacist involvement in a paediatric ward (in 
suggesting treatment options and identifying medication errors) resulted in reduced length of stay and 
improved drug compliance for patients with respiratory system diseases.
 29
   
  
A study conducted by Bond et al. has shown that the incorporation of several clinical pharmacy 
services (including pharmacist-provided drug use evaluation, in-service education, adverse drug 
reaction management, pharmacist participation on medical ward rounds and admission drug histories) 
were associated with reduced mortality rates in United States (US) hospitals.
6
 An association was 
shown between the number of clinical pharmacists per 100 occupied beds and reduced deaths per 
1000 hospital admissions.
6
 It was suggested that this study was only able to infer an association 
between clinical pharmacy services and mortality rates, but could not show causality, as it relied on 







Bond et al. suggested that the core set of pharmacist-provided clinical pharmacy services should 
incorporate the following: participation in cardiopulmonary resuscitation (CPR) teams, in-service 
education, adverse drug reaction (ADR) monitoring, drug information, medical round participation, 
drug protocol management and admission drug histories.
6
 A systematic review study conducted by 
Kaboli et al. suggested that involvement in ward rounds, interviewing patients, reconciling medication 
and providing patient discharge counselling and follow-up all improved patient outcomes.
31
 As these 
studies took place in US hospitals, where clinical pharmacy is more recognised, their applicability to 
South African hospitals may be limited. However, they may provide areas of key focus for the role of 
the clinical pharmacist during the establishment of these services in South African hospitals. 
 
All of the above-mentioned studies demonstrated the value of clinical pharmacy services in hospitals 
by improving patients’ clinical outcomes, their quality of life as well as by reduction in healthcare-
related costs. However, external validity is a limitation commonly identified in such studies, as few 
have been based on large multi-centre clinical trials of the introduction of clinical pharmacy services 
with appropriate controls. 
 
2.4 Clinical pharmacy in low- and middle-income countries 
 
Clinical pharmacy services in low- or middle-income countries are vastly different from those 
delivered in high-income countries. Clinical pharmacy in high-income countries has been developed 
and successfully integrated within stable drug management, drug distribution and regulatory 
mechanisms.
32
 However, in low- and middle-income countries, clinical pharmacy is seen as an 
isolated concept as these countries struggle to get core areas of drug distribution implemented and 
maintained safely and effectively.
32
 Without an effectively run medication distribution system in 
place, within urban and rural areas of a country, the exploration of other non-dispensing roles of the 
pharmacist is not considered to be of high priority. 
 
Pharmacists are recognised as a scarce skill occupation in low- and middle-income countries, and 
there is a need to increase pharmacist numbers to meet the health demands of such countries.
33
 Global 
observational surveys conducted by the World Health Organization (WHO) indicate that the number 
of pharmacists per 1000 population in low- and middle-income countries like South Africa (0.413 per 
1000 population, in 2012), India (0.501 per 1000 population, in 2012) and China (0.269 per 1000 
population, in 2011) are low when compared to high-income countries like the United Kingdom 
(0.812 per 1000 population, in 2013), Australia (1.016 per 1000 population, in 2012) and New 
Zealand (1.006 per 1000 population, in 2011).
34
 It is recognised by the FIP that in developing 




numbers of pharmaceutically-trained personnel increase, the role of the pharmacist could diversify 
into more clinical areas.
33
 The shortage of pharmacists makes the drug distributive task in developing 
countries a major challenge. Hawthorne and Anderson found that even though the available literature 
showed that the pharmacy curricula in developing countries were similar to those of developed 
countries, the highly competent individuals that graduated were not prepared for their particular 
countries’ demands, thus contributing to their frustration when entering practice.
35
 The results of this 
systematic review of the global pharmacy workforce showed that there is a greater migration of 
pharmacists from less developed to more developed countries.
35
 The health care needs and demands 
of the country greatly dictate the roles that the health care providers will need to provide. Only once 
stable drug delivery systems can be established and maintained will the demand for more patient-
focused clinical care begin to be met. 
 
South Africa is considered an upper middle-income country. In lower-middle income countries, like 
Pakistan, pharmacists are in a transition period where their role in patient care is not being fully 
explored due to the health systems challenges being experienced.
36
 The role of the pharmacist in 
improving the health care system is also not being recognised.
36
 To improve the clinical pharmacist 
role in these highly populous countries does not only require an increase in the number of qualified 
pharmacists but also an increase in appropriately trained pharmacists to provide that role. In India 
there is a large number of qualified pharmacists, however the pharmacy curriculum there is largely 
focused on the needs of the pharmaceutical industry.
36 
 
Babar et al. suggested that the barriers to effective pharmacy practice in low- and middle-income 
countries can be seen at a macro, meso and micro level.
11
 The underdevelopment of the health system 
itself could be hindering the further progress of these services at a macro level. The meso level is 
represented by the level and quality of the services the pharmacist is currently in a position to provide, 
which could either aid or hinder further effective pharmacy practice. Lastly, the micro level is 
represented by pharmacists themselves and the training and education they have to effectively 
implement this practice.
11
 The level of clinical pharmacy practice and other additional roles of the 
pharmacist cannot be considered to be the same for all countries that are deemed to be low- and 
middle-income, as there are vast regional differences in the level of the barriers described by Babar et 
al. More nationwide surveys, like the annual ASHP survey in the United States, need to be conducted 







2.5 Clinical pharmacy in South Africa 
 
Through the recent emergence of carbapenem-resistant Enterobacteriaceae (CRE) carrying the New 
Delhi metallo-β-lactamase-1 gene
37
 as well as Klebsiella pneumonia carbepenemases (KPC)
38
 in 
South Africa, the need for antibiotic stewardship programmes has gained prominance in both public 
and private sector hospitals. The Federation of Infectious Diseases Societies of Southern Africa 
(FIDSSA) arranged the first South African Antibiotic Stewardship Programme (SAASP) conference 
in February 2012.
39
 Through the development of these antibiotic stewardship programmes throughout 
hospitals in South Africa, the need for clinical pharmacy services aimed at monitoring antibiotic use 
has become more evident. This non-dispensing service has created a new role for the hospital 
pharmacist and has been the main focus of clinical pharmacy over recent years, particularly in private 
hospitals. In a 5-year prospective study conducted by Brink et al., non-specialist hospital pharmacists 
in the private sector have shown that they are able to achieve considerable improvements in the 
rational use of antibiotics.
40
 Antibiotic stewardship can be seen as the first step in clinical pharmacy 
service implementation in South Africa. However, clinical pharmacy involves complete drug therapy 
monitoring and management through the provision of pharmaceutical care. Clinical pharmacy in 
South Africa, like in many other low- and middle-income countries, is still very much in the early 
developmental stage. 
 
One of the major barriers to the progression of clinical pharmacy in South Africa is the lack of a 
specialist register at the SAPC. Currently, pharmacists in South Africa can gain entry to only two 
specialist registers,  as either a Radiopharmacist or a Pharmacokineticist.
41
 In December 2014, the 
SAPC issued Board Notice 152 of 2014, which proposed that the Minister would be asked to amend 
the “Regulations relating to the registration of persons and the maintenance of registers” to allow for 
the provision of 2 new pharmacist speciality categories, namely Clinical Pharmacist and Public Health 
Pharmacy and Management.
42
 For clinical pharmacist registration the proposed amendment requires a 
professional master’s degree (NQF level 9) which will be practice-based with a large component 
being work-integrated learning.
42
 To date there has not been any finalisation of the proposed 
amendments and registration as a specialist clinical pharmacist in South Africa is still not available. In 
the public sector there is a need for clinical pharmacist registration in order to implement the agreed 
occupation-specific dispensation (OSD). Clinical pharmacist posts can only be created once the SAPC 
introduces a register for this category.
43
 The way in which clinical pharmacists will eventually be 
incorporated in the private sector once the registration is eventually finalised remains to be seen. 
 
As mentioned above, pharmacy support staff play a major role in the development of clinical 




Africa, the pharmacy support staff cadre consists of pharmacist’s assistants, and very recently, the 
pharmacy technicians and pharmacy technical assistants. However, currently there is not yet a 
separate register for pharmacy technicians and pharmacy technical assistants, and those who have 
completed the newly accredited training are required to register as pharmacist’s assistants (post basic) 
with the SAPC.
44
 The course for pharmacy technicians was first approved and started in 2013 at the 
Nelson Mandela Metropolitan University (NMMU), with the first qualified technicians completing 




Pharmacy support staff, both pharmacist’s assistants (post basic) and pharmacy technicians in 
community and institutional pharmacies, are required by legislation to perform their roles strictly 
under the direct supervision of a pharmacist.
46
 Within primary health care clinics, both pharmacy 
technicians and pharmacist’s assistants (post basic) will require only indirect supervision by a 
pharmacist.
46
 As pharmacy technicians are to be a new introduction to pharmacist support cadre in 
South Africa, the full extent of their role in alleviating the dispensing and distributive roles of the 
pharmacist in community pharmacies and institutional pharmacies remains to be seen. Whether the 
roles of the pharmacy technician will follow those seen in the US and free pharmacists from the 
labour-intensive dispensing and drug distribution tasks is as yet unclear. Whether there will be 
sufficient recognition of the pharmacy technician role within hospitals in the private sector to create 
demand for this cadre is also of interest for the future. 
 
2.6 Clinical pharmacist training in high- and low-income countries 
 
The level of clinical pharmacy services provided in hospitals differs considerably amongst low-, 
middle- and high-income countries. This can be linked largely to the differences in education and 
training received by hospital pharmacists entering the hospital field as well as differences in the 
respective pharmacy practice needs within the country.  
 
In the US, growth and development of new drugs, increased number of authorised prescribers, broader 
medical insurance coverage and a need for an expanded scope of practice for pharmacists (amongst 
many other factors) led to a great increase in the demand for pharmaceutical services which could not 
be met by the existing workforce. This led to a nationwide pharmacist shortage in the late 1990s.
47
 
One factor aimed to alleviate the demand for the extended unmet needs of pharmaceutical care and 
the expanding roles of the pharmacist required to meet these needs, was the change from Bachelor of 
Science (B.S.) degree to the PharmD as the entry level degree for practising pharmacists by the 
Accreditation Council for Pharmacy Education (ACPE) in 2000.
47
 Clinical pharmacists can, after 




the residents’ knowledge on managing medication use systems and is focused on achieving optimal 
outcomes in a wide range of disease states.
48
 The second year (PGY2) increases the residents’ 
knowledge, skills and attitudes towards medication therapy management and clinical leadership 
within a selected speciality practice area.
48
 The American College of Clinical Pharmacy (ACCP) has 
created a strategic plan to ensure that the residency programme becomes the standard for pharmacists 
entering hospital practice in the US, as was summarised in the following statement on the future of the 
pharmacy profession: “Formal, postgraduate residency training will become mandatory before one 
can enter practice”.
49
 Residency programmes create a great advantage for clinical pharmacists 
working in the field.  
 
The ACCP has compiled a comprehensive list of core competencies that are required by a clinical 
pharmacist, once graduated from the PharmD or residency program, to enter the profession and 
provide the patient care and pharmacotherapy management that is needed.
48
 These competency 
statements are included in areas of “clinical problem solving, judgment, and decision making”, 
“communication and education”, medical information evaluation and management”, “management of 




In the UK, there has been a change from the 3-year Bachelor of Science (BSc) degree and one year 
pre-registration work to a 4-year MPharm program followed by a compulsory one-year work 
programme before one can register as a pharmacist with the General Pharmaceutical Council (GPC), 
which has taken over the regulatory role of the Royal Pharmaceutical Society of Great Britain 
(RPSGB).
50
 This degree is the shortest of the European pharmacy degrees, which generally range 
from 5 to 6 years.
50
 The Bologna principles stipulate that in order to enter a masters postgraduate 
degree one needs to complete a bachelors degree.
51
 The structure of the 4 year integrated MPharm 
qualification in the United Kingdom consists of 3 years at a bachelor level followed by one year at 
masters level and therefore complies with the Bologna principles of having to complete 2 cycles.
51
 
Damian Day, head of accreditation at the Royal Pharmaceutical Society at the time, stipulated that the 
MPharm qualification in the UK is not an undergraduate degree, as there is a possibility to only 




In 2008, the Pharmacy Council of India introduced the PharmD programme, which consists of six 
academic years (five years’ full-time study and one year of internship or residency in specialised 
units).
52
 This qualification exists alongside others, including the Diploma in Pharmacy (DipPharm), 
Bachelor of Pharmacy (BPharm), Master of Pharmacy (MPharm) and Doctor of Philosophy (PhD). 
The PharmD qualification contains a more standardised syllabus allowing better exposure to clinical 






many challenges are facing these PharmD students, including a lack of current awareness about 
PharmD courses and poor recruitment into Indian hospitals as clinical pharmacists by the Indian 
government, resulting in a scarcity of jobs for these newly-qualified graduates.
53
 The PharmD is thus 
not a standard pre-requisite to practise as a pharmacist in India.   
 
In South Africa, pharmacists are required to complete a 4-year undergraduate Bachelors degree 
(BPharm), followed by a year of pre-registration work (during which a final qualifying examination is 
written), followed by a year of community service experience in the public sector. Registration with 
the SAPC is a requirement to practise as a pharmacist in South Africa. There are a few Master of 
Pharmacy (MPharm) qualifications that are offered as well as one Doctor of Pharmacy (PharmD) 
programme.
14
 Currently the scope of practice of a pharmacist with or without postgraduate 
qualification is not mutually exclusive.
14
 As mentioned before, there is a proposal for a specialist 
clinical pharmacist register, but this has not been finalised.
42
 This proposal also called for the 
completion of a particular Master of Pharmacy programme as a requirement to register as a clinical 
pharmacist in South Africa, which will require 2 years of full-time postgraduate training.
42
 There is no 
mention of recognition of current qualifications or prior learning in meeting minimum requirements 
for registration.
14
 As was seen in India, it is unclear whether a specialised clinical pharmacy 
programme in South Africa (whether it be based on a new MPharm or PharmD programme) will be 
supported by sufficient demand through the creation of posts for clinical pharmacists in the public and 
private sectors. This support is necessary to make the specialist register viable in the long term and to 
ensure that the new roles are recognised and accepted by other healthcare providers. 
 
2.7 The Basel Statements  
 
The Basel Statements were initially set out by the Hospital Pharmacy Section (HPS) of the FIP in 
August 2008 in Basel, Switzerland.
7
 These statements were based on a global survey that was 
submitted to each of the 192 United Nations member states plus China-Taiwan, aimed at analysing 
the existing state of hospital pharmacy around the world.
54
 It resulted in a list of 75 statements 
carefully developed to reflect the ideal vision of pharmacy practice in a hospital pharmacy 
environment.
7
 Six aspects describing the full scope of the profession within the hospital setting were 
incorporated within these statements.
7
 The aspects include: medicines procurement, influence on 
prescribing, preparation and delivery of medicines, administration of medicines, monitoring of 
medicines as well as human resources and training.
7
 Clinical pharmacy services, being that of a 
provision of pharmaceutical care to the patient outside of normal dispensing processes, is clearly 





Table 2-1: The Basel Statements, influence on prescribing (BS26-BS32)
7
 
No. Basel Statement text 
26 Hospitals should utilize a medicine formulary system (local, regional, and/or national) 
linked to standard treatment guidelines, protocols, and treatment pathways based on the best 
available evidence. 
27 Hospital pharmacists should be members of pharmacy and therapeutics committees to 
oversee all medicines management policies and procedures, including those related to off-
label use and investigational medicines. 
28 Hospital pharmacists should have a key role in educating prescribers at all levels of training 
on the access to and evidence for optimal and appropriate use of medicines, including the 
required monitoring parameters and subsequent prescribing adjustments. 
29 Hospital pharmacists should be involved in all patient care areas to prospectively influence 
collaborative therapeutic decision-making. 
30 Hospital pharmacists should be an integral part of all patient rounds to assist with 
therapeutic decision-making and advise on clinical pharmacy and patient safety issues. 
31 Hospital pharmacists should provide continuity of care by transferring patient medicines 
information as patients move between sectors of care. 
32 Postgraduate clinical courses should be developed to prepare hospital pharmacists for 
collaborative prescribing of medicines, including instruction in legal and professional 
accountability; this role of hospital pharmacists should be promoted in the curricula of other 
health professionals. 
 
Since their inception, the Basel Statements have led to a series of independent studies being 
conducted across the globe, especially in the Western Pacific Region, to determine the extent to which 
current hospital pharmacy practice meets the desired standards.
12,55,56
 These studies also aid to create a 





Recently there has been a revision process for the Basel Statements which started in late 2011 and was 
finalised by the FIP HPS in September 2014 
8,57
 It was found that the majority of respondents 
involved in the voting process agreed that the Basel Statements were acceptable as written and did not 
need to be revised. After the revision process, a final total of 65 Basel Statements were agreed upon 
and accepted.
8,9
 The revision of the ‘influence on prescribing” aspect of the Basel Statements resulted 




statements were deemed to be appropriately worded and were not amended (they became revised 
Basel Statements 24 – 26). The next 3 revised Statements were reworded as follows:
9
           
Revised statement 27: Hospital pharmacists should be an integral part of the 
multidisciplinary team responsible for therapeutic decision making in all patient care 
areas. 
Revised statement 28: Hospital pharmacists should promote seamless care by 
contributing to the transfer of information about medicines whenever patients move 
between and within health care settings. 
Revised statement 29: Appropriately trained and credentialed hospital pharmacists 
should participate in collaborative prescribing. 
 
As discussed earlier, many studies have been conducted showing the importance or potential value of 
clinical pharmacy services in hospitals. However, there are many possible external factors (for 
example pharmacy staff structuring, hospital funding, governmental pressures) that could challenge 
the implementation of these services, and which may differ between countries. These factors can 
challenge the ability of achieving the vision of ideal pharmacy practice in a hospital environment, as 
set out in the Basel Statements.  
 
2.8 The hospital pharmacist’s perspective on clinical pharmacy 
 
A study conducted by Penm et al. set out to determine the views of hospital administrators, pharmacy 
directors and hospital pharmacists on the factors that are affecting clinical pharmacy service 
implementation in China.
12
 The interview guide used was developed based on seven of the Basel 
Statements, as shown in Table 2.1, and was administered as either a face-to-face interview or with a 
group of participants at a time.
12
 This study identified 3 themes highlighting the factors affecting 
clinical pharmacy services. The first factor, “external factors outside of pharmacy control”, explored 
governmental policies and areas of support or the lack thereof as well as a shortage of hospital 
funding in secondary hospitals to provide attractive salaries to highly trained pharmacists.
12
 Clinical 
pharmacists were also not seen as an income-generating healthcare professional (as compared to 
medical practitioners) for the hospital.
12
 The second theme of “resources for clinical pharmacy 
services” discussed the problem of a shortage of pharmacists and lack of sufficient clinical pharmacist 
training including the lack of proper formal evaluation of clinical pharmacists.
12
 The last theme, 
“expectations of clinical pharmacists and their self concept”, highlighted a lack of pharmacist self 




responsibility for drug therapy as problem factors.
12
 The perception of the idea of clinical pharmacy 
by other healthcare professionals was also a factor discussed in this study.  
 
A study such as that conducted by Penm et al. has not been done in South Africa, and would be of 
importance as hospital pharmacy practice develops a more clinical role. The focus of the present study 
is to explore the possible challenges to clinical pharmacy in South Africa, from the hospital 
pharmacists’ perspective. By identifying possible hindering factors we can begin to look at and 
develop strategies to overcome them and create a clinical pharmacist position that is recognised in 
South Africa.  
 
2.9 Theoretical Framework: The need for a pharmaceutical care system 
 
Clinical pharmacy aims to achieve pharmacotherapeutic objectives that enhance the patient’s quality 
of life, within a pharmaceutical care system.
3
 Clinical pharmacy therefore has at its core the provision 
of patient-specific pharmaceutical care.  
 
Hepler and Strand originally defined pharmaceutical care as “the responsible provision of drug 
therapy for the purpose of achieving definite outcomes that improve a patient’s quality of life”. They 
defined the desired outcomes as “(1) cure of a disease, (2) elimination or reduction of a patient’s 
symptomatology, (3) arresting or slowing of a disease process, or (4) preventing a disease or 
symptomatology”.
58
 Hepler and Strand further described that “pharmaceutical care involves a process 
through which a pharmacist cooperates with a patient and other professionals in designing, 





Over the past 50 years there has been a move away from the traditional apothecary role of preparation 
and selling of medicinal products to the role of dispenser of prefabricated drug products (during the 
rise of pharmaceutical industry in drug manufacture).
58
 The change of the primary role of the 
pharmacist limited to simply dispensing drugs based on a prescription order resulted in the pharmacist 
becoming “over-trained for what they did and under-utilised in relation to what they knew”.
59
   
 
Preventable drug-related morbidity and mortality remains a serious problem affecting healthcare 
today. These drug-related problems can be due to inappropriate prescribing, inappropriate drug 
delivery (where the medicine is either not available or due to dispensing errors), inappropriate 
behaviour of patients (non-compliance), patient idiosyncrasy (mistake/accident or idiosyncratic 
response in patient) and inappropriate monitoring.
58




and use of a pharmaceutical care system the rates of preventable drug-related morbidity and mortality 
can be reduced.
58  




The implementation of Pharmaceutical Care, while recognising the responsibility of 
the patient as end user of a medicine, required the pharmacist to use a range of 
processes to facilitate the responsible provision of medicinal treatment until tangible 
results are achieved, improving the patient’s quality of life.  
 
Improvement of the patient’s quality of life, reducing patient length of stay as well as reducing 
healthcare-related costs can all be associated with eliminating preventable drug-related morbidity and 
mortality. The pharmacist has a responsibility in preventing drug-related problems through increasing 
effectiveness of drug therapy as well as in monitoring and preventing adverse drug events.
58
 
Therefore, the adoption of a role that can meet the ever increasing demand for comprehensive 
pharmaceutical care services is required for the longevity of the profession. The professional purpose 







Chapter III: Methods 
 
Having considered the literature regarding clinical pharmacy in South Africa, the need to explore 
those barriers to its progression was identified. Identifying and investigating the views and attitudes of 
the hospital pharmacist of the challenges perceived towards clinical pharmacy development was thus 
the focus of this study. How these tools were developed and distributed and the results analysed is 
detailed within this chapter. 
 
3.1 Study Design 
 
Pharmaceutical care, a concept defined by Hepler and Strand in 1990,
58
 is the foundation of the role of 
the clinical pharmacist and thus formed the theoretical model that this study was based upon. This was 
an observational mixed methods research study comprising of both a qualitative first phase and a 
quantitative second phase. This study was conducted across 52 private hospitals within the same 
purposively selected private hospital group in South Africa. The researcher is employed by the same 
private hospital group, and so was able to obtain gatekeeper permission for the study and to negotiate 
access to staff members. The initial qualitative phase of this study consisted of semi-structured (one-
on-one) interview sessions and this was followed by a quantitative online survey phase.   
 
3.2 Phase 1: Qualitative Study 
 
The qualitative phase of this mixed methods research study was designed to deeply explore the views 
and attitudes of pharmacy managers towards clinical pharmacy services that are currently provided 
and the barriers that are being experienced with regard to its further implementation in the private 
hospital sector.   
 
3.2.1 Target Population 
The qualitative phase of this study involved the recruitment of pharmacy managers within the selected 
private hospital group. This population group was selected for the semi-structured interview sessions 
as the sample population would represent multiple hospitals. This would aid in obtaining a wide range 
of opinions and views on the topic as each hospital would only have one pharmacy manager 
contacted. Pharmacy managers were also expected to have more experience and knowledge of the 





3.2.2 Inclusion and Exclusion Criteria 
 
The population group for Phase 1 comprised of pharmacy managers only. Hospital pharmacists were 
excluded from this phase of the study. Pharmacist’s assistants, pharmacist interns and pharmacy 
students were excluded from this research study. 
 
3.2.3 Selection of the Study Population 
Non-probability sampling methods, and more specifically purposive sampling, were chosen for the 
qualitative phase, as this allowed for the selection of those individuals most knowledgeable about 
clinical pharmacy (i.e. hospital pharmacy managers) in order to get the most relevant information and 
feedback.  
 
The sampling methods used for the qualitative phase of this study were as follows. Firstly, a sampling 
frame in the form of an email list of all pharmacy managers was obtained. An initial email (with 
introduction letter and ethical approval forms), followed by subsequent reminder emails, were sent to 
all pharmacy managers within the population group requesting anyone interested in participating in a 
telephonic or face-to-face interview session to reply. In order to increase the number of respondents 
due to poor response, seven pharmacy managers were chosen from the email list and sent more 
personal requests for the interview session.   
 
3.2.4 Sample size considerations 
The qualitative phase of the study had a sample size target set at 10 to 15 respondents or until the 
point where no new themes emerged from the semi-structured interview sessions (saturation point).    
 
3.2.5 Collection of Data 
The semi-structured interviews were conducted face-to-face or telephonically depending on 
preference, convenience or accessibility. The interview questionnaire (see Appendix D) was drawn up 
based on the FIP Basel Statements on the Future of Hospital Pharmacy, as initially issued after the 
2008 Global Conference on the Future of Hospital Pharmacy (specifically BS26 to BS32).
7
 This was 
used as a guiding structure, but the interview was not restricted to these statements or questions. 
Informed consent was obtained from all respondents who were willing to participate. All interview 





3.2.6 Pilot Study 
The semi-structured interview was piloted on two pharmacy managers to determine their 
understanding of the questions asked and whether the questions were appropriate. The pilot study also 
helped determine the interview duration time, which was found to be an average of 45 minutes. 
 
3.2.7 Data Analysis 
All interview sessions were recorded and later transcribed as Word documents. Using a deductive 
approach to qualitative analysis, the transcript text was divided broadly into 3 groups: processes 
already in place within the hospital, perceived barriers to clinical pharmacy, and suggested ways of 
overcoming these barriers. Selective coding was then used to further categorise the data into common 
themes that emerged, related to these 3 broad categories. The qualitative data were then presented in 
thematic prose, with supporting quotes relating to the themes identified. 
 
3.3 Phase 2: Quantitative Study 
 
The quantitative phase of this mixed methods research study was designed to further explore the 
views and attitudes of pharmacists and pharmacy managers towards clinical pharmacy services in the 
private hospital sector, based on the themes identified during the qualitative phase of the study.  
 
3.3.1 Target Population 
The target population for the quantitative second phase of the study incorporated all permanently 
employed hospital pharmacists and pharmacy managers within the selected private hospital group.  
 
3.3.2 Inclusion and Exclusion Criteria 
This population group comprised of both dispensing and clinical pharmacists as well as pharmacy 
managers. Pharmacist’s assistants, pharmacist interns and pharmacy students were excluded from this 
research study. 
 
3.3.3 Selection of the Study Population 
The non-probability, purposive sampling method used for the quantitative phase involved obtaining a 
list of all hospital pharmacists currently employed within the hospital group. Only those pharmacists 
that were employed in the hospital environment and had an active email account were selected from 
this list (thus forming the sampling frame). An initial email (with introduction letter and ethical 
approval forms) followed by subsequent reminder emails were sent to all hospital pharmacists and 




online survey to follow the link included. The population size was 243 hospital pharmacists and 
pharmacy managers. 
 
3.3.4 Sample size considerations 
Response rates for survey questionnaires are generally expected to be low. Therefore the quantitative 
phase of this study had a sample population size target set at a minimum of 30% response rate. As the 
study was expected to be hypothesis-generating rather the hypothesis-testing in nature, no a priori 
assumptions could be used to support a formal sample size calculation. 
 
3.3.5 Collection of Data 
The quantitative survey questionnaire was drawn up partly based on the themes identified in the 
qualitative research phase. The survey was created electronically using the SurveyMonkey platform
61
 
and the access link was distributed to all pharmacists and pharmacy managers within the private 
hospital group via email. This internet-based self-completion questionnaire approach was chosen as it 
could quickly and easily be administered to the entire group. Such methods were also convenient for 
the participants, as they could complete the questionnaire in their own time. This method was also 
expected to reduce any potential interviewer effect or bias.  
 
3.3.6 Pilot Study 
The survey questionnaire was administered to 4 hospital pharmacists working within a selected 
private hospital in the group, to determine their understanding of questions asked and whether the 
questions were clearly worded and appropriate. The pilot study was used to determine whether there 
were any difficulties experienced with the internet survey (including access and ease of use). On the 
basis of the pilot study, the time to complete the survey was estimated to be about 15 minutes.  
 
3.3.7 Data Analysis 
All quantitative survey data was collated by the SurveyMonkey website and downloaded as a Portable 
Document Format (PDF) file. The individual respondent transcripts were then screened for 
completeness and accuracy and any invalid responses were omitted. All descriptive statistics were 
analysed and reported using Microsoft Excel. As this was an observational study, intended to be 








3.7 Bias and Limitations  
 
The study instrument was not formally validated. However, it was based on previously validated 
studies of Penm et al., conducted in the Western Pacific region.
12,55,56
 A pilot study was conducted 
beforehand to determine the face validity and applicability of the research tools to be used.  
 
This study incorporates the views and perspectives of hospital pharmacists and pharmacy managers 
within a single private hospital group and this could limit generalisability of results to all private 
hospital pharmacists in South Africa. Other private hospital groups could have different levels of 
clinical pharmacy services already implemented, which in turn may alter the perspectives of the 
hospital pharmacists employed there. The research tools used in this study (semi-structured interview 
and survey questionnaire) can however be applied to hospital pharmacists in other private hospital 
groups as well to hospital pharmacists in public hospitals in South Africa. 
 
As the survey questionnaire was being sent via email (all pharmacists and pharmacy managers should 
be provided with a work email address) the participant response rate was dependent on how regularly 
emails were checked. A second email was sent as a reminder and also to inform any participant who 
may have been on leave or out of office during time of the first email. Recently employed pharmacists 
(without operational email addresses as yet) could have been omitted from the population group.  
 
The survey link emailed to each participant was not specific to that individual respondent in order to 
ensure confidentiality. However, this meant that the survey could be filled out more than once by the 
same respondent. It was emphasized in all follow-up reminder emails that the survey should only be 
completed once per respondent.  
 
The survey required self-reporting, so the accuracy of data may therefore have been limited by the 
completeness and accuracy of the participants’ responses. The study was also limited to the number of 




The ethical approval for this study was obtained from the Biomedical Research Ethics Committee 
(BREC) of the University of KwaZulu-Natal (Reference number: BE264/15). The ethical approval 
letter is shown in Appendix A. Gatekeeper permission was obtained from the selected private hospital 





This study included a qualitative and a quantitative phase using semi-structured interviews and a 
survey questionnaire. There was no risk of social harm or any adverse effects to the participants for 
this study. The main ethical consideration that was addressed in the study is that of confidentiality and 
privacy. 
 
The semi-structured interviews were conducted face-to-face or telephonically, whichever was 
appropriate. Informed consent was obtained prior to the interview (see Appendix C – Informed 
consent document). The pharmacy manager’s personal identification details were not recorded during 
the interview and any demographic details that were required were not linked to the specific hospital 
pharmacy in which he/she was employed. The participant was informed fully of the intended research 
study and was asked whether he/she consented to the interview as well as to the audio recording of the 
interview. All recordings and transcripts of the semi-structured interview will be kept for maximum of 
6 months after the study (as password-protected computer files, only accessible by the researcher) 
after which it will be deleted. Each recording is kept under a coded number that will not be linked to 
participant identification. 
 
The survey was an internet-based questionnaire that was distributed via email.  The email contained 
only a link to the survey and was not linked with the email address of the respondent. There was no 
recording of any personal identification information on the survey questionnaire, only certain 
demographic information was requested. Each participant was informed of the intent of the study and 
was required to agree to informed consent in order to proceed. There are no incentives provided, nor 






Chapter IV: Results 
 
4.1 Introduction  
 
The data collection and analysis for this mixed methods research study was conducted using 2 phases: 
an initial qualitative phase using one-on-one interview sessions with pharmacy managers, followed by 
a quantitative phase involving the distribution of a survey questionnaire to all pharmacy managers and 
hospital pharmacists within the selected private hospital group.  
 
4.2 Phase 1 Qualitative study 
 
The qualitative study was developed to approach all pharmacy managers within the hospital group in 
order to comprehensively explore their views and attitudes towards clinical pharmacy services and the 
progression thereof in relation to the global ideal vision of hospital pharmacy practice as provided by 
the Basel Statements (BS26 to BS32).
7
    
 
4.2.1 Steps in the process 
The steps used in the implementation of the qualitative study were: 
1. A questionnaire based on the Basel Statements (BS26 to BS32)7 was developed, aimed at 
exploring the views and attitudes of pharmacy managers to clinical pharmacy services within 
their hospitals (see Appendix D). 
2. A pilot study was conducted with 2 pharmacy managers to determine the appropriateness and 
understanding of the questionnaire.  
3. An email list invitation was issued to all pharmacy managers within the private hospital group 
to participate in an interview session. 
4. The informed consent of willing participants for the interview was elicited (see Appendix C) 
5. In-depth, one-on-one, semi-structured interview sessions were held with all willing 
participants either face-to-face or telephonically. 
6. All transcripts were transcribed and then thematically analysed. 
7. The themes and results of the qualitative study were incorporated in the construction of the 
survey instrument for the quantitative study.   
 
4.2.2 Pilot study and response rate 
The first 2 semi-structured interviews were conducted face-to-face and were used as pilot study 




interpreted without ambiguity. The pilot interviews did however help to determine the most efficient 
arrangement of questioning to allow for ease of thematic flow of ideas without unnecessary 
interruption back and forth. It was also determined that an average of 45 minutes was needed to 
complete the session. The remaining five interviews were conducted telephonically due to 
convenience and logistical reasons. These interview sessions were held during October and November 
2015. As no changes to the instrument were made, the pilot interviews were included in the final 
sample. 
 
A total of 7 interviews were therefore conducted with 6 pharmacy managers and one regional clinical 
pharmacist from various hospitals of the same selected private hospital group within South Africa. 
The clinical pharmacist was included in the interview sample due to poor response received from 
pharmacy managers to repeated email requests for interviews. An initial email request and subsequent 
reminder email together with an introduction sheet, consent form and ethical approval forms were sent 
out to 44 pharmacy managers in the group in September and October 2015 and only two responses 
were received. As the response rate was very poor it was decided to send out more personalised email 
requests to 7 selected pharmacy managers from the population list. From this request a further 3 
pharmacy managers were willing to participate in the interview session. Unfortunately, the initial 
minimum target set of 10 respondents was not achieved. However, after the 7 individual semi-
structured interview sessions were held no new themes seemed to emerge and therefore the 
investigation was deemed to have reached saturation. The ultimate response rate was therefore 7/44 
(15.9%). 
 
4.2.3 Demographics: Hospital pharmacy managers 
The 7 respondents interviewed were between the ages of 30 to 41 years, with the majority being 
female (5 respondents; 71.4%). The 6 pharmacy managers interviewed had 7 to 10 years’ of 
managerial experience, except for one manager who had only been appointed recently (7 months’ 
experience). All interviewees had a BPharm degree as their highest qualification, with one pharmacy 
manager in the process of studying towards a Master’s degree. The clinical pharmacist was the only 
respondent currently with a Master’s degree. The 7 interviewees were referred to as PM 1 to PM 7 
during the transcript analysis. 
 
4.2.4 Thematic Analysis: Structural and Behavioural Factors 
After thematic analysis of all 7 interview transcripts, certain closely linked common themes started to 
emerge and could be isolated. The factors that hinder the progression of clinical pharmacy services 
within these private hospitals were categorised into structural and behavioural factors.  The structural 




operational factors and hospital and governmental influence. These three structural factors are already 
in place and to a large extent are not under the pharmacists’ or even pharmacy managers’ control. The 
behavioural factors are internal factors of a personalised nature and centre around the individual staff 
pharmacists’ needs and attitudes. The sections that follow expand on these factors with supporting 
verbatim quotes highlighting the perceived barriers to implementing clinical pharmacy and possible 
methods of how to overcome them. 
 
4.2.4.1 Educational Factors 
Educational factors, and in particular the current level of knowledge of the pharmacist was one of the 
most commonly identified factors perceived by pharmacy managers to be hindering clinical pharmacy 
development in South African private hospitals. It also appeared to be a key area of focus for starting 
to overcome these barriers to aid the progression of clinical pharmacy service development.  
 
There is a need for pharmacists to take personal responsibility for their own clinical knowledge as the 
current knowledge shortfall results in the pharmacist only performing minimum (basic) level 
pharmaceutical (clinical) interventions. PM 4 mentioned that: 
 
“pharmacists must improve their own knowledge...not think they know, they must 
know...pharmacists want to do interventions but don’t have the background or 
knowledge to back themselves up”.  
 
PM 4 went on further and explained that the hospital group head office is trying to implement certain 
restriction criteria to preserve newer antibiotic agents and prevent inappropriate use, but pharmacists 
struggle to enforce these policies due to their lack of clinical knowledge and the need for 
individualisation of each patient case.  
 
PM 1 mentioned that the clinical knowledge of the pharmacist (gained during the undergraduate 
degree) tends to decrease from the community service year, as the community service pharmacist’s 
work tends to be more focused on stock procurement and logistic tasks rather than clinical work. 
Furthermore, the interview sessions revealed that clinical pharmacy needs to be promoted in the 
curricula of other healthcare providers, but before this can successfully be done the clinical 
knowledge of the pharmacist needs to be improved. PM 2 mentioned the following in relation to 
promoting the role of the clinical pharmacist in the curricular of other healthcare professionals:  
 
“It will make a difference but we first need to be up-skilled to promote it. Doctors will be 




need to be at that level [of clinical knowledge] to build the relationship and establish 
that trust.”  
 
The lack of practical application of clinical knowledge was also mentioned as a challenging factor for 
clinical pharmacy services being provided by the hospital pharmacist. PM 6 mentioned that 
pharmacists generally lack physical interaction at ward level, especially when medicines are being 
administered and therefore are not exposed to the observed/experienced effects of commonly used 
medicines, as opposed to the theoretical effects:  
 
“I find that we know the mechanism of action of drugs, but in nursing they see the 
reversal or impact of the drug. If we are more in contact with those experiences it will 
better our clinical knowledge.” (PM 6) 
 
“Pharmacists in SA haven’t really been involved in therapeutic drug monitoring...where 
we are trained in these. With the pressures of having a hospital and retail combination 
pharmacy one loses the ability to check all those factors or one tends to forget.” (PM 1) 
 
Specialisation was mentioned a number of times during the interview sessions as one way of 
overcoming the challenge to clinical pharmacy due to poor clinical knowledge:  
 
“Specialising will empower the pharmacist to study further and to give them 
accountability and responsibility. The doctor will now have a ‘go to’ person for a 
specific field of medicine.” (PM 7) 
 
“I feel that pharmacists should be able to specialise in certain fields because there are so 
many facets of pharmacy, as currently they expect the clinical pharmacist to be a 
specialist in all types of medicines.” (PM 1) 
 
PM 1 also mentioned specialisation in relation to clinical pharmacists acting as medicine consultants 
and through a mutual trust greatly enhancing the therapeutic relationship with the attending 
prescriber. This in turn was expected to increase the pharmacist’s responsibility for patient care:  
 
“If a person is a specialist in a field, as pharmacists in South Africa are more 
generalists, and they educate people around them, they will in turn make themselves 




person and build trust that will increase the therapeutic relationship between doctor and 
pharmacist. The pharmacist will in turn take up more accountability.”  
 
Apart from specialisation, one of the interview respondents (PM 4) mentioned the importance of 
pharmacists improving their knowledge of specific areas of medicine, areas in which they are meant 
to be very knowledgeable or better trained in (e.g. pharmacokinetics, pharmacodynamics and 
pharmacology). Where there may be a gap in the prescriber’s knowledge, the pharmacist can aid with 
specific patient dose calculations or by providing continuing professional development (CPD) training 
to medical practitioners. 
 
It was generally agreed that post-graduate clinical courses need to be made available to prepare 
clinical pharmacists for the field. In reference to clinical pharmacists needing a post-graduate degree 
in order to practise as such, PM 4 mentioned the following:   
 
“I think the pharmacist that works as a clinical pharmacist needs the degree to back 
them up, but this is still not the case as it is still a new role...if you don’t have the degree 
you must equip yourself with the correct knowledge to work as a clinical pharmacist.”  
 
In contrast to this position, it was also mentioned during the interview sessions that clinical material 
should be included in the undergraduate degree and not only as a separate post-graduate degree: 
 
“I feel it should be part of the course [BPharm undergraduate degree] and this course 
should be longer...if it is post-graduate, then most pharmacists won’t do it but if it is part 
of the course you are forced to do it. As you start working, the financial implications are 
challenging to study post-graduate courses.” (PM 6) 
 
University pharmacy undergraduate courses should be standardised and more clinically focused to aid 
the pharmacist when starting a career as a hospital pharmacist. PM 2 mentioned that universities 
should be made aware of the needs and goals of clinical pharmacists in private hospital practice:  
 
“We need to speak to the universities and say this is our goal, this is where we lacking 
knowledge and confidence...this is what we deal with and this is our environment, what 
learning material can be given.” (PM 2) 
 
It was suggested that courses for clinical pharmacy development should include training on literature 




also thought to improve the knowledge and research skill set of the clinical pharmacist. In response to 
the level at which pharmacists currently are able to intervene with therapy prescribed by medical 
practitioners in private hospital, PM 1 mentioned that:  
 
“there is minimum intervention required although if one has access to the literature there 
is input that the pharmacist can give, but don’t know whether all pharmacists are 
comfortable or empowered enough to do it.”  
 
Apart from formal training it was mentioned that there should be regular modules and testing being 
done to ensure that the clinical pharmacists’ knowledge remains at a high standard.  
 
“Modules should be done on a monthly basis and testing should be enforced. We must 
put the standard higher and there must be incentive. This should be done with nursing 
too. We need to empower the nurses as well.” (PM 2) 
 
“We [hospital pharmacists] can play a much bigger role. The doctors in South Africa 
should start acknowledging the pharmacist, and we should start playing that role...we 
should have the knowledge to do it.” (PM 2) 
 
4.2.4.2 Pharmacy Operational Factors 
The pharmacy operational factors identified during analysis of the interview transcripts that pose a 
significant challenge to clinical pharmacy service development within private hospitals were: 
 a lack of time available for clinical work; and  
 current staffing levels and staff structure requirements. 
 
There are many other time-consuming daily activities that challenge the amount of clinical work the 
hospital pharmacist can do or that could be done. In response to their view of the current level of 
clinical pharmacy in South Africa, PM 2 said that there is:  
 
“still a lot to learn and a lot to do, but we can go a lot further if we have more resources 
to just do clinical work...if we could have 2 clinical pharmacists just doing clinical work it 
would help us a lot.” 
 





“Your [the hospital pharmacist’s] priority is inpatient dispensing. If medication isn’t 
given you can’t do any clinical work. It becomes a ‘toss-up’ between using your 
pharmacists to dispense or having them doing clinical work...I think the [staff] structure 
needs to be changed a bit.” (PM 7)  
 
It was mentioned that there is often not enough time to get to the wards to counsel the inpatients on 
their medication and this task is often left to the nursing staff. Lack of available time creates a 
challenge for the pharmacist to attend to all inpatients especially those difficult patient cases which 
often require more attention. One of the pharmacy managers mentioned that: 
 
“A doctor has a patient list and can decide to block out his/her schedule to spend more 
time on a specific case. However, in hospital pharmacy if you have a difficult case you 
cannot block out the other patients, because you must attend to other patient scripts. It is 
more difficult to focus in on a specific case...it’s a workload/time problem.” (PM 1) 
 
Meetings (such as meeting of the Drug and Therapeutics Committee, Medicine Safety Committee, 
Antibiotic Stewardship Committee) are considered time-consuming and are often not a high priority, 
especially in hospitals with limited staffing. If these meetings are not well organized and resourceful 
they can be seen as time-wasting:  
 
“Some hospitals see medication safety meetings as something they have to do, not as 
something that is important to do... there are a lot [of hospitals] who are on board [with 
having DTC meetings in place] but there are still a few small hospitals where there may 
only be one pharmacist available. Here it’s not because they don’t want to, but because 
there is so much other work to do [e.g. dispensing] that is more important than having a 
committee for medication safety...sometimes there is just not enough staff for all these to 
happen.”  (PM 4)  
 
In terms of current staffing levels and staffing structures within private hospital pharmacies, it was 
mentioned that monetary constraints in South Africa and the current poor economy play a major role 
in hindering the progression of clinical services. To get sufficient staffing in order to run the best 
clinical service based on a “pharmacist per X patient” ratio are a hindering factor as the return on 
investment may not immediately be identified. PM 1 explained that adjusting staffing ratios is very 





“Currently the mindset of pharmacy is to show us return on investment before we can 
increase [staffing] ratios. However, we need to increase ratios in order to offer the best 
clinical pharmacy services and the benefits will follow from there. Unfortunately, we 
have monetary constraints in South Africa.” 
 
PM 5 explained that good staffing models need to be determined based on hospital specific statistics, 
including minutes per patient needed as well as number of hospital beds to determine the minimum 
number of pharmacists to cover all beds. These should then be compared to international standards. A 
lack of time available and staff shortage are factors hindering the progression of clinical pharmacy 
services. Automated dispensing units were suggested as a possible aid to help free up time for the 
pharmacist to provide more clinical services and to follow up on therapeutic outcomes of the patient:  
 
“Probably one of the only other ways forward is when you start automating. Looking at 
a cost effective way of staffing and resourcing, probably automated dispensers are the 
only way to go.” (PM 5) 
 
“I think it [automated dispensing units] is fantastic. Stock management and picking 
scripts takes up a lot of time...you don’t need a degree to take tablets off the shelf. There 
will be less pressure and more time for clinical work and counselling patients in retail.” 
(PM 2) 
 
However, negative comments were also mentioned about the use of automation in private hospitals. 
PM 3 was not in full agreement with resorting to automation as it did not seem practical at the 
moment, as it would be very costly and still required much labour and time to keep the units stocked. 
PM 4 also mentioned that even though there would be more free time available for pharmacists to do 
clinical work in the wards, hospital pharmacists would still need to ensure that base-level dispensing 
was performed correctly.   
 
Incorporating pharmacy technicians in the hospital was also identified as a possible means to 
overcome staff shortages. PM 7 mentioned that pharmacy technicians could help with clinical work 
(data collection, etc) as well as stabilise the task of dispensing in order to free up the pharmacist for 
more clinical work. However, technicians can be a costly expense (as mentioned by PM 5), and 





Another way of overcoming these barriers is to focus on educating and up-skilling the nursing staff. 
This could greatly ease the challenge that staff shortages pose to clinical pharmacy progression as the 
perceived workload of the clinical pharmacist could be minimised. PM 2 mentioned that:  
 
“we [pharmacists] are scarce skills...we don’t need to be involved with every patient and 
hand out medication but we can up-skill our nurses.”   
 
Given the resources currently at hand, there were different opinions as to how clinical pharmacy 
services should be implemented in the hospital. PM 3 mentioned that clinical pharmacy services 
should be performed on a rotational basis (i.e. hospital pharmacists rotate the clinical role amongst 
themselves) where the pharmacy provides one service and there is not a distinction between the 
clinical and staff pharmacists. It was further suggested that, by using a rotational approach, all 
pharmacists could share their knowledge and discuss patient cases, but if distinctions are made 
between pharmacists this would not happen. This can be considered as a “team” approach to clinical 
pharmacy services. 
 
In contrast to this approach, PM 4 mentioned that clinical services should not be rotational as specific 
people with a keen interest and dedication to clinical work should rather be selected. The rotational 
method was seen as a forced approach to clinical pharmacy, as a ‘have to’ and not a ‘want to’ service. 
 
4.2.4.3 Hospital and Governmental Influence 
The factors identified as challenging clinical pharmacy service development within private hospitals 
were influenced both from within the individual hospitals or the hospital group as well as from other 
external forces or governmental involvement.  
 
One of the commonly identified challenging factors to the progression of clinical pharmacy is linked 
to the fact that medical practitioners working in the private sector in South Africa are not employed by 
the hospital and are thus working in their own private capacity: 
 
“The doctor is not in our employ and decides on each patient and how they would like to 
treat. Doctors do have their own protocols (e.g. for pain control) that they follow, but it 
is not standardised as a treatment as a whole but for each individual treating doctor.” 
(PM 1) 
 
PM 7 also mentioned during the interview that medical practitioners have been given free reign in 




follows his/her own guidelines in prescribing, this creates difficulty for clinical pharmacists when 
approaching such prescribers and questioning their choices. This was elaborated by PM 5 who 
mentioned:  
 
“Each doctor being in their private capacity, check guidelines according to their own 
standards and are not subscribing to a minimum standard. There’s no consistency, no 
governance and no one checks whether these guidelines are right or wrong...doctors 
generally don’t regularly review their own guidelines as there is no governance. They 
are not subscribing to any clinical governance structure.”  
 
Due to medical practitioners working in their own private capacity, this poses a challenge to get 
prescribers involved in Drug and Therapeutics Committee (DTC) or Antibiotic Stewardship 
Committees (ASC). When discussing DTC meetings and doctor involvement, PM 5 mentioned that: 
 
“the biggest challenge is to get doctor buy-in [in antibiotic stewardship committee 
meetings]. A lot of doctors see it as a waste of time as they don’t get paid for it. Time is 
money in their private capacity.” 
 
A change in structure, where medical practitioners are employed by private hospitals, will also result 
in a change in accountability and responsibility for the patient’s clinical outcome: 
 
“Doctors are in their own private capacity, so ultimately they are responsible. If doctors 
are employed and subscribe to clinical governance of the hospital their involvement will 
be part of a multidisciplinary approach [to treating the patient] then all are involved and 
accountable.” (PM 5) 
 
Medical practitioners and nurses in private health care tend not to understand the role of the clinical 
pharmacist at ward level. Clinical pharmacy is a fairly new development in hospital pharmacy and the 
defined role of the clinical pharmacist is not covered in the current curriculum of other healthcare 
professionals. PM 7 mentioned that nurses often do not see the pharmacist as contributing to patient 
outcomes, but merely as a dispenser of products. The role of the clinical pharmacist is also 
misunderstood by patients. This may also be a contributing factor to a lack of pharmacist interaction 
with the patient at ward level:  
 
“Patients corner a pharmacist with uncomfortable questions that they may not be able to 




pharmacist [in the wards]. Patient education is vital to understand the role of the clinical 
pharmacist and to expect that.” (PM 1) 
 
“Unfortunately pharmacists are not at the patient bedside enough to be involved in 
patient care and collaborative decision making. This only happens when we are 
contacted by the doctor or nursing sister or the patient themselves wants more 
information. Problem is to get pharmacists to the bedside...Once the pharmacists can 
move out into the wards; we can add much more value to patient care.” (PM 1) 
 
One of the first steps in overcoming the barriers to clinical pharmacy development within private 
hospital is for the need for a clinical pharmacist role to be recognised, established and clearly defined 
by the South African Pharmacy Council (SAPC). As stated by PM 7:  
 
“Government needs to define the roles of clinical pharmacists clearly.”  
 
Once the role of the clinical pharmacist is clearly defined by the SAPC it can be incorporated in the 
curricula of other healthcare professionals. Patient education and understanding of the role of clinical 
pharmacist will eventually follow and create a need for greater involvement by the clinical 
pharmacist. PM 5 mentioned the following with regard to patient education on the clinical 
pharmacist’s role: 
 
“[Patient education] will come naturally if you educate the nurses and doctors [of the 
clinical pharmacist role], who can then inform the patient that the pharmacist will be 
around and look at and explain your medicine. Multidisciplinary approach must be right 
from the foundation stage with all disciplines.” 
 
Pharmacists need to bridge the perceived gap in therapeutic relationship with the treating medical 
practitioners. As clinical pharmacy services develop, this gap may intensify due to a lack of a clear 
understanding of this new pharmacist role. PM 4 mentioned the importance of:  
 
“bettering our relationship with the doctors, so that they can see we are there to help 
and not there as a threat and telling them what to do. It’s one of the biggest challenges 






A similar point was made by PM 5: 
 
“It involves getting [the doctor] buy in but also you [the pharmacist] must show your 
worth. You must show the intervention you are making as benefiting the patient or 
adding quality to their work. The younger doctors are generally more co-operative with 
this, but this takes time.” 
 
The DTC and ASC meetings should be more frequently and efficiently used as a tool to build 
therapeutic relationships with other healthcare professionals. However, due to the difficulty in getting 
medical practitioner involvement at these meetings, PM 5 further explained that the younger, more 
innovative medical practitioners tend to be more involved and should therefore be approached, but 
that it is vital that the pharmacists’ clinical knowledge remain up to standard and consistent. 
 
Another challenge experience in private hospitals is the lack of support in terms of a career path for 
clinical pharmacists. PM 5 mentioned that once a pharmacist qualifies with a post-graduate degree 
there is no specific position that could be offered to retain the pharmacist within private hospital 
environment (other than as a senior pharmacist in a management, as opposed to clinical, position). 
There has been a lot of effort placed into developing clinical work, but unfortunately retaining 
pharmacists once they qualify remains a challenge. 
 
It was also mentioned by respondents that there is a lack of a nationally-implemented clinical 
pharmacy programme for both the private and public sectors. The implementation of various forms of 
clinical work through hospital pharmacy has been used as a platform to compete with other private 
hospital groups. PM 6 mentioned that in order for clinical pharmacy to progress in South Africa, there 
should be a general set standard of clinical pharmacy services implemented in private and public 
hospitals that is driven nationally from the Department of Health or another national structure. There 
will always be uncertainty if each individual hospital group pursues its own idea of what constitutes 
clinical pharmacy, but the impact will be more marked and lasting if consensus is reached on a 
nationally-implemented and nationally-driven standard. 
 
4.2.4.4 Behavioural Factors 
Apart from the structural factors discussed above, a separate theme also emerged during thematic 
analysis of the interview transcripts identified as behavioural factors. These factors hindering the 
progression of clinical pharmacy can be classified as internal factors as they are individualised and are 





One of the biggest challenges mentioned by respondents was that of the individual pharmacist’s 
attitude towards change. PM 4 mentioned that many pharmacists are not comfortable in the ward 
environment but will be happy to work daily in their ‘safe zone’ of the pharmacy:  
 
“They don’t feel comfortable about going to the wards and interacting with the patient 
and asking questions.” 
 
The shortfall in clinical knowledge and low commitment to CPD are major contributing factors to the 
lack of self-confidence experienced by many pharmacists: 
 
“The pharmacist’s role is to advise the drugs and say what should be used...but we don’t 
have the knowledge; we need to go and study up. We feel insecure about ourselves when 
going on ward rounds, we then keep quiet...it’s our own fault, currently we don’t have 
the confidence.” (PM 2)  
 
It is vital to overcome that initial first step in clinical pharmacy and this has been achieved through 
forcing the pharmacist into the ward environment and increasing interaction with patients and other 
healthcare providers in the clinical setting: 
 
“When you force the issue through Bluebird
1
 [antibiotic stewardship applications] or 
going on daily ICU ward rounds, it doesn’t take long for that mindset to change. It’s just 
a matter of time...you need to force the issue, which then forces you to read up and learn 
and that itself helps to gain further confidence.” (PM 5) 
 
4.2.5 Summary 
Overall, the thematic analysis of the key informant interviews with pharmacy managers (and one 
clinical pharmacist) revealed a series of key factors hampering the development of clinical pharmacy 
in the private hospital environment in South Africa. Addressing each of these identified factors 
provides potential avenues for remedial action, to promote such development in the country, for the 
benefit of patients. The identified themes also allowed for the development of a suitable instrument 
for the second, quantitative phase of the study. 
 
  
                                                          
1
 Bluebird is a software suite used as an antimicrobial stewardship tool that allows the clinical pharmacist to 




4.3 Phase 2 Quantitative Study 
 
The purpose of the quantitative study was to further explore those themes and results captured during 
the interviews with pharmacy managers, by means of a survey instrument directed at all pharmacists 
in the selected private hospital group.  
 
4.3.1 Steps in the process 
The steps followed in the implementation of the quantitative study were: 
1. The development of a questionnaire incorporating the themes and results of the interview 
sessions conducted during the qualitative phase of the study (see Appendix E). 
2. Conduct of a pilot study with 4 hospital pharmacists to determine the appropriateness and 
understanding of the survey tool and questionnaire.  
3. An invitation to all pharmacy managers and hospital pharmacists within the selected private 
hospital group, using the study population email list, to participate in an online survey. 
4. The elicitation of informed consent from all willing participants before the start of the survey. 
5. Capture, extraction, cleaning and analysis of the resultant quantitative data. 
 
4.3.2 Pilot study 
The quantitative online survey followed the qualitative semi-structured interview sessions. During the 
survey pilot study the survey questionnaire was given to 4 hospital pharmacists to read and review for 
clarity and interpretation of the questions during November 2015. The pilot study also helped to 
assess the data collection tool used, SurveyMonkey
61
, on ease of use and understanding. There was no 
misinterpretation of any question and no changes needed to be made prior to data collection. It was 
determined that the average time to complete the survey was 15 minutes.   
 
4.3.3 Survey distribution and response rate 
The survey link together with an introduction sheet and ethical approval forms were emailed to 243 
pharmacists and pharmacy managers within the selected private hospital group in November 2015. A 
second reminder email was sent in December 2015 after which a total of 60 responses were received 
by the initial deadline date set. Due to the poor response, the deadline was extended and a further 2 
emails were sent out to the group during January and February 2016. In total, 74 responses (30.4% 
response rate) were included for analysis.  
 
4.3.4 Demographics: Hospital pharmacy managers and pharmacists 
The survey respondents were mainly within the 30 to 39 year age group (30/74; 40.5%), with the 




than a Bachelor’s degree, with only 21/74 respondents (28.3%) having already completed a Master’s 
degree (MPharm, MSc or MBA) and a further 2 respondents specifying that they are in the process of 
completing their Master’s degree. It was also noticed that a large proportion of the respondent hospital 
pharmacists (33/74; 44.6%) were in a senior position (as either pharmacy managers or senior 
pharmacists). 
 
Table 4-1: Demographic Details – Hospital pharmacy managers and pharmacists 
Parameter Category Number % 
Age Years   
 20 – 29 20 27.0 
 30 – 39 30 40.5 
 40 – 49 15 20.3 
 50 – 59 7 9.5 
 60 or older 2 2.7 
Sex    
 Female 64 86.5 
 Male 10 13.5 
Highest Qualification  
 
 
 Diploma 2 2.7 
 Bachelor’s 48 64.9 
 MPharm 11 14.9 
 MSc 7 9.5 
 PharmD 0 0.00 








Table 4-1: Demographic Details – Hospital pharmacy managers and pharmacists 
(continued) 
 
Occupational title  
 
 




 Senior Pharmacist 11 14.9 
 Pharmacy Manager 21 28.4 
     Other** 1 1.4 
*Responses: Final year MPharm; BPharm and BSc Hons Pharmacology; Honours in 
pharmacology; Honours; Currently doing MPharm; BPharm MBA. 
**Response: Retail Pharmacy Manager 
NOTE: Private hospital pharmacies may also run a separate retail component that 
services the community in addition to the inpatient hospital pharmacy service.  
 
The survey respondents generally comprised of pharmacists fairly new to hospital pharmacy. The 
median number of years of experience as a qualified pharmacist was 5 to 9 years (interquartile range 
(IQR): 5 - 19 years) and as a hospital pharmacist, 5 to 9 years (IQR: 0 - 19 years). Of the total sample 
population, 26/74 respondents (35.1%) had 0 to 4 years hospital pharmacy experience. The 
distribution of years of experience as a qualified pharmacist and as a hospital pharmacist in particular, 
is shown in Figure 4.1.   
 
 
Figure 4-1: Years of Experience of Pharmacists 
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4.3.5 Demographics: Hospital 
Only 73 respondents provided data on the hospital size and staffing. The respondent pharmacists 
worked in hospitals with 50 to over 500 beds. The median hospital size was 200-299 beds (IQR: 100 - 
399 beds) with 3 intensive care units (ICU) (IQR 2-4) per hospital. The majority of respondents 
worked in medium-sized hospitals of 100 to 299 beds (41/73; 56.2%). The distribution of hospital size 
and number of ICUs is shown in Table 4.2. 
 
The hospitals in which respondents worked had a median staff component of 6 pharmacists (IQR: 4-7) 
and 6 pharmaceutical support staff (IQR: 4-7). Almost half of all respondents (35/73; 48.0%) worked 
in the pharmacy with 7 or more pharmaceutical support staff members. This level of support staff 
provision most commonly identified in hospitals with 200 to 499 beds. The distribution of the number 
of pharmacists and pharmaceutical support staff in hospitals from which responses were received is 





Table 4-2: Demographic Details – Hospital 
Parameter Category Number % 
Number of hospital beds < 50 1 1.4 
n = 73 50 – 99 3 4.1 
 100 – 199 21 28.8 
 200 – 299 20 27.4 
 300 – 399 13 17.8 
 400 – 499 10 13.7 
 > 500 5 6.9 
Number of ICUs  
 
 
n = 73 0 0 0.00 
 1 17 23.3 
 2 19 26.0 
 3 11 15.1 
 4 13 17.8 
 >/= 5 13 17.8 
Total number of pharmacists  
 
 
n = 73 </= 2 2 2.7 
 3 7 9.6 
 4 15 20.6 
 5 10 15.1 
 6 13 17.8 





Table 4-2: Demographic Details – Hospital (continued) 
Total number of pharmaceutical support staff    
n = 73 </= 2 9 12.3 
 3 2 2.7 
 4 10 13.7 
 5 8 11.0 
 6 9 12.3 
 >/= 7 35 48.0 
Total number of clinical/ward pharmacists  
 
 
n = 73 0 8 11.0 
 1 27 37.0 
 2 14 19.2 
 3 10 13.7 
 4 7 9.6 
 >/= 5 7 9.6 
 
When comparing hospital size to number of pharmacists, it can be seen that hospitals with 400 or 
more beds were staffed with at least 7 pharmacists (see Figure 4.2). In the 100 to 199 bed hospitals, 4 
full-time employed pharmacists were most commonly identified as the staffing level. However, in 






Figure 4-2: Number of hospital pharmacists compared to hospital size 
 
Although a median of 2 (IQR: 1-3) clinical pharmacists were reported per hospital, 37% (27/73) of 
respondents stated that there was only 1 clinical or ward pharmacist appointed in their hospital (see 
Table 4.2). At least one clinical pharmacist was identified in all hospital size groups, and most clearly 
evident within the 100 to 199 and 200 to 299 bed hospitals. It can also be seen that 8/73 respondents 
(11.0%) noted that there were no clinical pharmacists present within their hospitals.   
 
4.3.6 Role of the pharmacist: Priority ranking of daily tasks 
The survey respondents were all asked to rank 6 daily activities, in the form of a Likert scale, 
according to what they considered the highest to lowest priority. The number of respondents that 
provided data for rating each activity varied from 60 to 69. The activities chosen were those most 
commonly performed within hospitals by pharmacy personnel. As can be seen in Figure 4.3, the two 
most noticeable activities rated in the highest priority scale (combined ratings of 1 and 2) were 
dispensing (41/60; 68.3%) and ward rounds (38/65; 58.5%). The three activities most commonly rated 
to be lower priority activities and falling within the lower priority scale (combined ratings of 5 and 6) 
were administrative work (35/66; 53.0%), education and training of other healthcare professionals 













































Figure 4-3: Priority ranking of daily hospital pharmacist activities 
 
When asked what approximate percentage of time pharmacists spend daily on these 6 activities, 
respondents reported that dispensing and ward rounds are tasks that occupy most of the pharmacist’s 
time. The median percentage of time that pharmacists spent on dispensing was reported to be 37.5% 
(IQR: 10-50%) with only 17.5% (IQR: 6.25-30%) of time is spent on ward rounds. The activities that 
that occupied the least amount of time were stock procurement and control as well as education and 
training of other healthcare providers, both at a median of 5% (IQR: 5-10%). 
 
Pharmacy managers made up 28.4% (21/74) of the total survey sample population (shown in Table 
4.1) and due to the different daily tasks and requirements of this position, these responses were more 
closely analysed. The number of pharmacy manager respondents that provided data for rating each 
activity varied from 15 to 19. The 2 highest priority activities assigned to the pharmacy manager 
remained dispensing (11/15; 73.3%) and ward rounds (9/19; 47.7%) as shown in Figure 4.4. Only two 
activities were noticeably considered to have lower priority, these being administrative work (9/17; 
52.9%) and education and training of other healthcare providers (8/19; 42.1%). 



































Figure 4-4: Priority ranking of daily pharmacy manager activities 
 
The percentage of time that pharmacy managers specifically spend on these daily activities showed 
that the least amount of time is allocated to education and training of other healthcare professionals 
with a median of 5% (IQR: 5-10%). Patient counselling as well as stock procurement and control both 
had a median of 10% (IQR: 5-10% and 5-13.5% respectively) of daily time spent performing these 
tasks. A median of 50% of pharmacy manager’s time is allocated to administrative work however this 
high value was not consistently recognized as variable responses are reflected in the large IQR (15-
60%). 
 
4.3.7 Drug and Therapeutic Committee and Antibiotic Stewardship Committee involvement 
When the survey respondents were asked whether or not a DTC that regularly meet was present in the 
hospital, 55.4% (41/74) said yes, 37.8% (28/74) said no and 6.8% (5/74) did not respond, as is shown 
in Table 4.3. Looking closer at the hospitals with a DTC present, it was seen that at least one 
pharmacist was involved in this multidisciplinary committee. It was most frequently stated that 1 
pharmacist (14/41; 34.1%) is currently involved in the DTC meetings within their hospital followed 
by 5 or more pharmacists (11/41; 26.8%).  
 
In terms of an antibiotic stewardship, 91.9% (68/74) of survey respondents stated that there was an 
antibiotic stewardship programme implemented in their hospital and 87.8% (65/74) stated that there 
currently was an Antibiotic Stewardship Committee (ASC) that regularly meet within the hospital. Of 



































was a member of the multidisciplinary team. It was most frequently stated that 1 pharmacist (17/65; 
26.2%) is involved within this committee. 
 
Table 4-3: Pharmacist involvement in DTC and ASC 
Parameter Category Number % 




n = 74 Yes 41 55.4 
 No 28 37.8 
 No response 5 6.8 
Number of pharmacists currently involved in DTC.  
 
 
n = 69 0 9 13.0 
 1 16 23.2 
 2 7 10.1 
 3 8 11.6 
 4 3 4.4 
 >/= 5 11 15.9 
 N/A 15 21.7 
Number of pharmacists currently involved in DTC.  
 
 
(of the 41 respondents who stated that a DTC was 
present)  
0 0 0 
 1 14 34.1 
 2 7 17.1 
 3 6 14.6 
 4 3 7.3 
 >/= 5 11 26.8 




Table 4-3: Pharmacist involvement in DTC and ASC (continued) 
 
Is there an antibiotic stewardship programme 




n = 74 Yes 68 91.9 
 No 1 1.4 
 No response 5 6.8 





n = 74 Yes 65 87.8 
 No 5 6.8 
 No response 4 5.4 
Number of pharmacists currently involved in ASC.    
n = 69 0 1 1.5 
 1 18 26.1 
 2 15 21.7 
 3 12 17.4 
 4 7 10.1 
 >/= 5 14 20.3 
 N/A 2 2.9 
Number of pharmacists currently involved in ASC.  
 
 
(of the 65 respondents who stated that an ASC was 
present)  
0 0 0 
 1 17 26.2 
 2 15 23.1 




Table 4-3: Pharmacist involvement in DTC and ASC (continued) 
 
 
 4 7 10.8 
 >/= 5 13 20.0 
 N/A 0 0 
 
4.3.8 Clinical pharmacy overview  
The survey respondents were asked to what extent they agreed or disagreed with statements related to 
clinical pharmacy as practised within private hospitals. The statements tested were derived from the 
thematic analysis conducted as part of the qualitative phase. Only 69 respondents provided data for 
this question. The responses are presented in Table 4.4 and Figure 4.5.   
 
With reference to education and training it can clearly be seen that 100% (69/69) of the survey 
respondents, who answered this question, agreed (with 57/69; 82.6% strongly agreeing) to the 
statement that ‘Further formal education or training courses are required for pharmacists to provide 
efficient clinical pharmacy services’. It was also revealed that 94.2% (65/69) of the survey 
respondents also believed that it is the responsibility of the pharmacist to be primary providers of 
medication information and training to both doctors and nurses. 
 
Multidisciplinary ward rounds can be considered an area of focus in building professional therapeutic 
relationships. Of all the survey respondents, 84.1% (58/69) completely agreed that with regular multi-
disciplinary ward rounds professional therapeutic relationships can be created and collaborative 
prescribing practices promoted within the hospital. 
 
The idea of an increased responsibility being attributed to the clinical pharmacist for the patient’s 
clinical outcomes as a means to enhance clinical pharmacy services was agreed with by 87.0% 
(60/69) of survey respondents.  
 
In terms of using dispensing aids as a means to enhance clinical pharmacy progression, 79.7% (55/69) 
of the survey respondents believed that the use of robot dispensing and technicians could to some 





Table 4-4: Level of agreement regarding statements related to clinical pharmacy 
Indicate your level of 





















1. Clinical pharmacy 
services should be the 






3 (4.4%) 3 (4.4%) 2 (2.9%) 69 
2. Use of pharmacy 
technicians and robot 
dispensing could be 







6 (8.7%) 6 (8.7%) 2 (2.9%) 69 
3. Hospital pharmacists 










3 (4.4%) 1 (1.5%) 0 (0.0%) 69 
4. Further formal 
education or training 
courses are required 








0 (0.0%) 0 (0.0%) 0 (0.0%) 69 
5. Clinical pharmacists 














Table 4-4: Level of agreement regarding statements related to clinical pharmacy (continued) 
6. Regular multi-
disciplinary ward 










0 (0.0%) 0 (0.0%) 1 (1.5%) 69 
7. The clinical 
pharmacist’s role is 
clearly structured and 










4 (5.8%) 69 
 
 
Figure 4-5: Level of agreement regarding statements related to clinical pharmacy 
 
4.3.9 The progression of clinical pharmacy 
The survey respondents were further asked whether they felt that certain factors obtained during 
thematic analysis of the qualitative data would have a negative or positive effect on the progression of 
clinical pharmacy services as one of the primary roles of the clinical pharmacist. The number of 
respondents that provided data for each statement varied from 65 to 67. Their responses can be seen in 
Table 4.5 and Figure 4.6.   
The clinical pharmacist’s role is clearly structured and 
understood by hospital pharmacists 
Regular multi-disciplinary ward rounds will create professional 
therapeutic relationships and promote collaborative … 
Clinical pharmacists should carry more responsibility for 
patient’s clinical outcome 
Further formal education or training courses are required for 
pharmacists to provide efficient clinical pharmacy services 
Hospital pharmacists should be the primary providers of 
medication information and training to doctors and nurses 
Use of pharmacy technicians and robot dispensing could be 
beneficial for clinical pharmacy service development 
Clinical pharmacy services should be the priority role of the 




Neither Agree nor Disagree 
1 - 4.4% 
2 - 8.7% 
3 - 4.4%  
4 - 0.0%  
5 - 10.1% 
6 - 0.0% 





A large majority of the survey respondents (55/67; 82.1%) stated that the inclusion of post-graduate 
clinical courses will have a positive/somewhat positive effect on the progression of clinical pharmacy 
services as a primary role of the hospital pharmacist. Of the survey respondents, 56.9% (37/65) felt 
that their level of confidence in their own clinical knowledge was a hindering factor on the 
progression of clinical pharmacy services. It can be seen that 83.6% (56/67) of the survey respondents 
stated that influence and support from hospital management is a key factor that will enhance the 
progression of clinical pharmacy services in private hospitals.  
 
Direct patient interaction and involvement at ward level was said to have, to some extent, a positive 
effect on clinical pharmacy service progression by 78.8% (52/66) of the survey respondents. It can 
also be seen that the level of understanding of the role of the clinical pharmacist as seen by other 
healthcare professionals (HCPs) is essential for the progression of clinical pharmacy services as one 
of the primary roles of the hospital pharmacist, with 71.6% (48/67) of the survey respondents in 
agreement. It was further recognized, by 77.6% (52/67) of the respondents, that support from other 
HCPs is also required to further the progression of clinical pharmacy services.  
 
In reference to pharmacy operational factors, 76.1% (51/67) of the survey respondents felt that the 
current availability of time for clinical pharmaceutical services was a hindering factor towards the 
progression of clinical pharmacy services as one of the primary roles of the hospital pharmacist. It 
was further seen that the current staffing structure had a negative effect on clinical pharmacy service 
progression, with which 71.6% (48/67) of the respondents agreed.  
 
With 70.8% (46/65) of survey respondents in agreement, it was identified that the introduction of a 
clinical pharmacist registration with the SAPC is vital to further progress clinical pharmacy services 














Table 4-5: Direct effect of factors towards the progression of clinical pharmacy services 
What effect do you feel the 
following factors have on 
progression of clinical 
pharmacy services as one of 






















3 (4.5%) 10 
(14.9%) 
6 (9.0%) 67 







1 (1.5%) 8 (11.9%) 7 (10.5%) 67 






2 (3.1%) 21 
(32.3%) 
5 (7.7%) 65 
4. Post-graduate clinical 
courses being made 
available 







5. Clinical pharmacist 
registration with the SAPC 







6. B.Pharm degree studied in 
clinical pharmacist 
preparation at hospital 
level 







7. Level of understanding of 
the role of the clinical 
pharmacist 
1 (1.5%) 14 
(20.9%) 





8. Level of hospital inpatients 
understanding of the role 
of the clinical pharmacist  












10. Level of understanding of 
the role of the clinical 












Table 4-5: Direct effect of factors towards the progression of clinical pharmacy services (continued) 
 
11. Direct patient interaction 
and involvement at ward 
level 







12. Influence and support from 
governmental 
organisations  







13. Influence and support from 
hospital management 





14. Other? Please specify* 
 open communication channels between healthcare professionals and respect for the different 
healthcare professions among health care professionals 
 The current focus on Antibiotic Stewardship (only) is having a negative effect on the Clinical 
Pharmacy as patients are not evaluated holistically but only antibiotic medication are reviewed and 
evaluated. 
 BPharm does not sufficiently prepare pharmacists for a role in clinical pharmacy. It is very science 




Figure 4-6: Direct effect of factors in support of the progression of clinical pharmacy services 
Current staffing structure 
Availability of time for clinical pharmaceutical services 
Level of confidence in own clinical knowledge 
Post-graduate clinical courses being made available 
Clinical pharmacist registration with the SAPC 
B.Pharm degree studied in clinical pharmacist … 
Level of understanding of the role of the clinical … 
Level of hospital inpatients understanding of the role of … 
Support from other HCPs 
Level of understanding of the role of the clinical … 
Direct patient interaction and involvement at ward level 
Influence and support from governmental organisations 
Influence and support from hospital management 
Negative Effect 
Somewhat Negative Effect 
Has No Effect 





4.3.10 Additional comments on the barriers to clinical pharmacy progression and possible ways to 
overcome them 
The survey respondents were further asked if there were any other factors they felt were hindering 
clinical pharmacy progression and if they had any suggestions for possible solutions. All respondents 
were coded as R1 to R74 for reference.     
In terms of education and training, respondent R53 stated:  
 
“I think more ‘in-house’ CPD’s and training would be beneficial for all pharmacists who 
are required to participate in clinical services.”  
 
Another respondent (R12) also stated that online and interactive short courses should be made 
available to give hospital pharmacists the opportunity to pursue clinical work without having to 
complete a post-graduate degree (which, due to financial constraints or family obligations, may not be 
a possibility). The lack of a residency type program where newly qualified clinical pharmacists can 
learn from experienced clinical pharmacists through a practical approach was mentioned by 
respondent R7 as a barrier to clinical pharmacy progression in South Africa.  
 
Respondent R25 mentioned that there is inconsistency between the different hospitals of the group in 
the amount of clinical work the pharmacist is able to do. This is due to some hospitals having a 
number of clinical pharmacists while others have no pharmacists in a specific clinical pharmacist 
position: 
 
“Pharmacists are employed in a dispensing position and then do ward/clinical work as a 
small fraction of their job.” (R25)   
 
Another respondent (R7) stated that: 
 
“Clinical pharmacists are spread between different private and public hospital groups 
with different visions for clinical pharmacy.”  
 
This lack of direction, or common goal for clinical pharmacy, is hampering its progression in the 
country. 
 
Lack of incentive and motivation was also mentioned as a potential barrier to clinical pharmacy 
within private hospital. Respondent R41 suggested that if legislation could change, whereby a 




all “behind the scenes” services that are rendered, this could enable employers to employ a pharmacist 
to specifically offer clinical services. Clinical pharmacy could in turn be expanded to all inpatients.   
The behavioural factors commonly hindering pharmacists from taking up the clinical pharmacy role 
was emphasized by respondent R43:  
 
“The progression of clinical pharmacy services is based entirely on a pharmacist[‘s] 




This study investigated the views and attitudes of pharmacy managers and hospital pharmacists 
towards clinical pharmacy and the barriers to its progression in the private hospital environment. Key 
informant interviews and the subsequent thematic analysis thereof exposed these hindering factors as 
external structural factors and internal behavioural factors. The external factors, being out of the 
pharmacist and pharmacy manager’s control, could be grouped into educational factors, pharmacy 
operational factors and hospital and governmental influence. The internal factors considered to be 
individualized and under the pharmacist’s control, incorporated their self-confidence and attitude 
towards change. 
 
The structural and behavioural themes analysed during the first phase of this study allowed for the 
development of a quantitative survey tool to further explore these factors and their influence on 
clinical pharmacy progression. Hospital pharmacists of clinical, dispensing and managerial 
background gave insight into the level of clinical pharmacy within the private setting and to what 
extent these factors are hindering its progress. The significance of these findings within the South 
African setting and how they compare to similar studies conducted in other countries will expose 
areas in which remedial action can be taken. The first step in advancing the development of clinical 
pharmacy services and the recognition of the pharmacist as a clinical partner in improving patient care 






Chapter V: Discussion 
 
The factors hindering the progression of clinical pharmacy in private hospitals in South Africa consist 
both of internal factors, such as the individual pharmacist’s attitude towards change, and external 
factors, which are often out of the pharmacist’s control. This chapter discusses all the perceived 
barriers to clinical pharmacy services in the South African private hospital sector identified in the 
study, places these in the context of the available literature, and suggests ways in which these barriers 
could be overcome. The chapter also discusses the use of the FIP Basel Statements on the Future of 
Hospital Pharmacy as a tool for monitoring clinical pharmacy progression within the hospital sector.  
 
The perceived barriers, and the means to address them, were elucidated in exploratory interviews with 
pharmacy managers from a single, large private hospital group in South Africa, and then confirmed 
and quantified by means of a survey among pharmacists in the same group. 
 
5.1 Educational needs and self-confidence   
 
The provision of clinical pharmacy services as a non-distributory or non-dispensing role of the private 
hospital pharmacist faces several hindering factors, and the pharmacists’ lack of clinical knowledge is 
one most commonly identified. In the quantitative portion of the study, all the survey respondents 
agreed with the statement that ‘Further formal education or training courses are required for 
pharmacists to provide efficient clinical pharmacy services’. The need to provide clinical training and 
further develop the clinical knowledge of hospital pharmacists is essential in effectively establishing 
and maintaining this role.  
 
The lack of appropriate and applicable clinical knowledge, as a barrier to clinical pharmacy 
progression, has been revealed in studies conducted in other low- and middle-income countries.
12,32,62
 
Kheir et al. conducted a review of the literature related to pharmacy education and practice in 13 
countries in the Arabic-speaking traditional Middle Eastern region.
62
 They identified a need to 
restructure pharmacy undergraduate curricula to focus more on the provision of patient care skills 
through experiential training, in order to provide the clinical knowledge that the expanding role of the 
pharmacist demands.
62
 In an attempt to provide more clinically advanced professionals, several 
pharmacy schools in these countries have introduced PharmD programmes as entry-level 
qualifications.
62
 These countries have sought accreditation with the US Accreditation Council for 
Pharmacy Education (ACPE), and have chosen to align their pharmacy curricula with the US model, 




research study into the factors directly affecting clinical pharmacy service implementation in Chinese 
hospitals.
12
 Hospital administrators, pharmacy directors, clinical pharmacists and dispensing 
pharmacists from 29 tertiary and secondary hospitals in different areas of China were interviewed. 
One of the barriers to clinical pharmacy identified in this study was the negative effect a lack of 
clinical knowledge had on the pharmacist’s self-confidence.
12
 Respondents felt that the amount of 
clinical training received was inadequate to prepare pharmacists for clinical roles. Added to this, a 
limited number of training positions were offered for clinical pharmacists in China, resulting in many 
pharmacists being unable to upgrade their skills as required.
12
 The study by Penm et al. drew attention 
to multiple other factors affecting clinical pharmacy progression in Chinese hospitals. As both China 
and South Africa are upper middle-income countries, these comparisons have been explored more 
extensively in this chapter. 
 
A study conducted by Ngorsuraches and Li in 2006 determined the perceived barriers and attitudes of 
pharmacists to providing pharmaceutical care services in Thailand, another upper middle-income 
country, through a self-administered questionnaire.
63
 This study was not restricted to the views of 
hospital pharmacists as community sector pharmacists were also included. However, 83.4% of the 
respondents in this study were from the hospital sector. One of the major barriers to pharmaceutical 
care revealed was a lack of therapeutic knowledge and clinical problem-solving skills of the 




One potential determining factor of the degree to which pharmacists feel confident to deliver clinical 
services is their initial professional education and training. The pharmacy undergraduate degree 
differs considerably between medium- and high-income countries, where clinical pharmacy is more 
established. The ACPE has endorsed the PharmD degree as the entry-level requirement for practising 
pharmacists in that country. Over time, this has replaced all baccalaureate level qualifications in the 
US. Although commonly perceived as a 6-year qualification, many PharmDs are 4-year graduate 
programmes, which enroll students who already hold a college degree. Importantly, though the first 3 
years of most PharmD programmes include the usual foundational courses in the Pharmacy majors, 
they also include introductory experiential learning opportunities in Pharmacy Practice. The final, 4
th
 
year of the PharmD programme is usually an advanced pharmacy practice experience, with extensive 
exposure to healthcare settings, and in particular to the teaching hospitals to which Pharmacy Schools 
in the US are affiliated. In addition, it has become increasingly common for hospital pharmacists in 
the US to have completed a 1- or 2-year residency program, leading to board certification as a 
pharmacy specialist.
47,48
 In the United Kingdom (UK), as in the rest of Europe, the Bologna-inspired 
harmonisation of professional education has seen the introduction of a 4-year integrated MPharm 
programme.
50




experience. It must be emphasised that the UK schooling system requires 13 years to complete the 
Advanced (A) level qualification on which university entrance is based, compared to the 12 years to 
complete the National Senior Certificate in South Africa. A 4-year MPharm is thus the equivalent of a 
5-year qualification in South Africa. In many European countries, such as France and The 
Netherlands, the PharmD is now commonly offered. In The Netherlands, designation as a hospital 
pharmacist requires the completion of a post-graduate qualification, beyond the entry level 
qualification, and formal certification. In many Dutch teaching hospitals, this training is sometimes 
linked to a structured doctoral programme, leading to a PhD qualification. In an attempt to provide 
more clinically advanced professionals, the introduction of the PharmD programme as an entry-level 
qualification is increasingly seen in low- and middle-income countries, such as India, Pakistan, 
Bangladesh and parts of the Middle East.
64
 Clinical pharmacy progression in these countries have, 
however, been challenged by the shortage of qualified clinical pharmacists to act as preceptors of 
mentors.
64 
   
In South Africa, the 4 year BPharm undergraduate degree has replaced the Diploma in Pharmacy as 
the qualification leading to professional registration. However, another year of pre-registration 
internship has to be completed in the community, institutional (hospital), industrial or academic 
setting, during which time the final qualifying examination set by the South African Pharmacy 
Council has to be successfully completed. After registration as a pharmacist, graduates who have 
completed the internship and final qualifying examination also have to complete a further year of 
community service in the public sector, before being able to practice in a setting of their choosing. 
Although providing some experience in an institutional setting (usually a hospital, although some 
community service pharmacists are also placed in primary care facilities, provincial stores, military or 
correctional services facilities, or even, most recently, at the national medicines regulatory authority), 
the community service year is not intended to be part of the training of a pharmacist. Therefore, all 
that is required for a pharmacist to practise within the public or private hospital sector is completion 
of the BPharm, an internship in any setting and the final qualifying examination (which is partly 
specific to the setting in which the internship was completed).  As respondent PM 1 mentioned during 
the interview session, the clinical knowledge that a new pharmacy graduate obtains during the 
undergraduate degree tends to not be enhanced or applied during the community service year as the 
work performed is often more focused on stock procurement and logistic tasks as opposed to clinical 
work. In the South African model, as in many other low- and middle-income countries, the perceived 
health care need (primarily seen in the public sector) is to run safe and effective medication 
distribution systems, rather than the provision of sophisticated clinical pharmacy services.
32
 The 
undergraduate degree often accommodates needs-based education models to supply professionals 




of more developed practice.
65
 Only once these priorities are being met, can adaptation of the 
pharmacy programme to incorporate global views be considered.
65
 The FIP, in its global vision for 
education and workforce published in 2016, acknowledged that a needs-based, outcomes-focused 
approach to continuing education and training should be the foundation of pharmaceutical workforce 
development.
66
 The FIP has stated that “[a]n evolving pharmaceutical workforce is one that can adapt 
its core roles and responsibilities to meet the new and emerging needs of patients and civil society.”
66
 
As the demand for pharmaceutical care focused services is becoming more evident, and pressing, in 
South African private hospitals, the local pharmacy curricula need to adapt to supply professionals 
capable of meeting this demand. Relying on the few South African pharmacists who have completed 
post-baccalaureate PharmD or clinical pharmacy MPharm programmes in the US, UK and elsewhere 
will not suffice. The necessary capacity must be home-grown, and appropriate to the needs of local 
practice, at the requisite level of clinical sophistication.     
 
The introduction of post-graduate clinical pharmacy courses, as suggested by respondent PM 4, was 
supported by 82.1% of the survey respondents. The lack of clinical knowledge as a barrier and the 
need for further structured courses to provide competent clinical pharmacists has also been recognised 
in other low- and middle-income countries. A study conducted by Penm et al., on factors affecting the 
implementation of clinical pharmacy services in China, found that many clinical pharmacists agreed 
that the current training model used in China was considered “insufficient or inappropriate to 
implement”.
12
 However, in South Africa, the introduction of such course, leading to a specialist 
registration as a clinical pharmacist has followed a contested and protracted course. The proposed 
amendment to the “Regulations relating to the registration of persons and the maintenance of 
registers” for inclusion of registration as a clinical pharmacist is still pending approval.
42
 The Board 
Notice 152 of 2014, issued be the South African Pharmacy Council, expresses the need for a specific, 
newly-designed and extensive post-graduate Master of Pharmacy qualification as the minimum 
requirement for registration as a clinical pharmacist.
42
 There is no acknowledgment of existing post-
graduate MPharm or even post-baccalaureate PharmD qualifications, or of clinical courses/training 
that may already have been undertaken by hospital pharmacists, which might constitute the grounds of 
recognition of prior learning (RPL).  
 
Before any overly restrictive methods for registration as a clinical pharmacist are implemented, a 
more inclusive approach to incorporate prior clinical training and education should be considered. The 
Board of Pharmacy Specialties (BPS) is an independent structure, established in 1976 by the 
American Pharmacy Association, focused on providing post-licensure specialty certification to the 
pharmacy profession.
67
 The BPS certification provides a means for qualified pharmacists to 






 Recertification is required every seven years to ensure that the 
knowledge and skill of the pharmacist is maintained at a high level. BPS certification “enables 
pharmacists to differentiate and affirm their knowledge and skills to provide more comprehensive 
patient care; be prepared to step into pharmacy’s evolving position on the integrated 
multidisciplinary treatment team; and be recognized for their expertise by healthcare professionals, 
employers, insurers and patients”.
67
 Currently there are eight pharmacy practice specialties offered by 
the BPS, these being: ambulatory care pharmacy, critical care pharmacy, nuclear pharmacy, 
nutritional support pharmacy, oncology pharmacy, paediatric pharmacy, pharmacotherapy and 
psychiatric pharmacy.
67
 A certified system of clinical knowledge assessment based on the educational 
requirements attributed to the clinical pharmacist role, along with a structured process of 
recertification, will be a beneficial alternative to the post-graduate degree as the sole minimum 
requirement for clinical pharmacist specialist registration in South Africa. 
 
As the proposals for clinical pharmacist registration in South Africa are still in draft form, and have 
yet to get the explicit support of the Department of Health or the Minister, the formalisation of the 
proposed clinical pharmacy speciality qualification and register is likely to be delayed. Both public 
and private sector hospitals are therefore unlikely to see the provision of a supply of qualified 
registered clinical pharmacists for some years. As a result, the need to follow international educational 
trends and restructure the undergraduate degree for pharmacists has been recognised, as a means of 
ensuring that those entering the hospital environment are competent to provide standardised and 
adequate clinical pharmacy services. Respondents PM6 and R12 mentioned that financial constraints 
and family obligations hinder further post-graduate study for those entering the working environment. 
However, a separate post-graduate degree would provide a bridging option for those currently in the 
field to pursue the title and registration and should be provided until undergraduate supply meets 
future demand.  
 
In the interim, until a structured clinical pharmacist course is established, other methods of training 
were suggested by the respondents in this study. The need to specialise was a concept suggested to aid 
the progression of clinical pharmacy services. As mentioned by PM 7: “Specialising will empower the 
pharmacist to study further and to give them accountability and responsibility. The doctor will now 
have a ‘go to’ person for a specific field of medicine.” To specialise or to adopt an integrated model to 
provide continuity of care, a model used by 64.7% of US hospitals in 2009,
68
 is important to consider 
if specialised models and training are to be implemented. For example, it was found that clinical 
pharmacists in China were unsure of their responsibilities as a specialist pharmacist and found being a 
generalist pharmacist more useful.
12




particular roles, such as the provision of pharmacokinetic advice, as mentioned by PM 4, as the 




Antibiotic stewardship in South Africa is following global trends to combat the spread of antibiotic 
resistance, and its implementation has been particularly marked in the private hospital sector.
40
 This 
has allowed hospital pharmacists to engage with a non-distributory, more specialised clinical role in 
patient care.
40
 Branching out and adopting other similar roles will aid the progression of clinical 
pharmacy, provided clinical training along with regular modules and testing (as suggested by PM 2) 
are in place to ensure the pharmacists’ knowledge remains at a high standard. Performance- or 
competency-based criteria have been used internationally to aid in clinical pharmacy progression and 
should be considered within the hospital group.
12
 Survey respondent R53 also mentioned the 
importance of continuing professional development (CPD): “I think more ‘in-house’ CPD’s and 
training would be beneficial for all pharmacists who are required to participate in clinical services”. 
CPD training modules and programmes should be promoted within the hospital group to ensure the 
level of clinical knowledge of the hospital pharmacist is raised and that it is current and evidence-
based. The FIP has recently highlighted the importance of CPD systems as an essential means of 
“maintaining and advancing the competencies and capabilities of pharmacists and pharmaceutical 
scientists throughout their careers”.
66 
 
Poor self-confidence in providing clinical services is closely linked to the pharmacists’ lack of clinical 
knowledge and training, with 56.9% of the survey respondents agreeing that their level of confidence 
in their own clinical knowledge was a hindering factor to the progression of clinical pharmacy 
services. Poor self-confidence is also linked to uncertainty and lack of clear understanding of their 
new role. The South African hospital pharmacist is entering a transition period and the progression of 
this new clinical role is dependent largely on how the pharmacist can adapt to this change, given the 
other external barriers to clinical pharmacy progression. As respondent R43 mentioned: “The 
progression of clinical pharmacy services is based entirely on a pharmacist[‘s] willingness to learn 
and change”.     
 
5.2 Resource allocation for clinical pharmacy progression 
  
A lack of available time for clinical work, linked to current staffing levels and staff structure 
requirements, was identified as a key barrier to clinical pharmacy services in South African private 
hospitals. Pharmacy is considered to be a scarce skill occupation in South Africa. WHO global 
observational surveys indicated that, in 2012, there were 0.413 pharmacists per 1000 population in 






 Both the UK and Australia are high-income countries, whereas South Africa 
is an upper middle-income country. The number of pharmacists in other upper middle-income 
countries according to the WHO global observational surveys in 2011 was 0.269 and 0.354 
pharmacists per 1000 population in China and Turkey, respectively.
34
 There are currently 13 981 
registered pharmacists in South Africa.
20
 In 2012, 43% of the pharmacists on the register were 
employed in the community pharmacy sector, followed by 35% in hospital settings.
69
 There is already 
a need to meet the medication distribution demands of the community with low pharmacist numbers, 
and as it was mentioned by PM 7, the priority role of the pharmacist in many hospital settings is in-
patient dispensing which takes precedence over clinical services. The shortage of pharmacists was 
also a factor seen as affecting clinical pharmacy service implementation in China.
12
 When it comes to 
assigning resources in smaller hospitals, tasks considered to be of lower priority (e.g. DTC meetings 
and clinical work) are not regularly met, as pharmacists are allocated preferentially to what are 
perceived to be higher priority roles, and in particular medication distributive roles. The lack of 
human resources also affects high-income settings. For example, the 2015 American Society of 
Health-System Pharmacists (ASHP) national survey showed that only 44.6% of US hospitals with 
fewer than 50 beds provided drug therapy management to patients compared to 85.3% of hospitals 
with 600 or more beds.
70
 The lack of time to provide pharmaceutical care services was also a barrier 




The survey respondents revealed that dispensing was considered to enjoy the highest priority for 
pharmacists in private hospitals, followed by ward rounds. It was further shown that most of the 
pharmacists’ time was allocated to these high priority tasks: dispensing (37.5%) and ward rounds 
(17.5%), while only 5% of time is spent on education and training as well as on stock 
procurement/control. According to the 2015 ASHP national survey, 43.8% of the US hospital 
pharmacists’ time was spent on order review and verification (medication order or prescription review 





To determine the ideal staffing structure and staffing levels required per hospital to provide 
sustainable clinical pharmacy services without negatively affecting medication dispensing services is 
difficult. It was suggested by respondent PM 5 that staffing models should be based on hospital-
specific statistics, such as the number of hospital beds, and the time required per patient to provide the 
desired clinical services. While the first piece of data is easily obtained, the second depends on the 
types of beds, case mix, and the specific services to be delivered, and is very difficult to determine 
with any accuracy. With a median of 6 pharmacists and 2 clinical pharmacists per hospital within the 




providing clinical services to meet the pharmaceutical care needs of all patients appeared to be 
impossible. In this regard, the contrast with US data is informative. The 2015 ASHP national survey 
showed that the average number of pharmacist full-time equivalents (FTE) was 11.4 per hospital, with 
an additional 11.0 FTE pharmacy technician per hospital. Pharmacist and technician FTEs varied with 
hospital size.
24
 Across all US hospitals surveyed, there was an average of 15.6 pharmacist FTEs and 
14.8 pharmacy technician FTEs per 100 occupied beds.
24
 In South Africa, the idea of 30 pharmacists 
and 30 pharmacist’s assistants (post-basic) per 200-bed hospital (with 100% bed occupancy) seems 
fanciful to say the least. In Canadian hospitals the idea of capping the number of patients under the 
care of the clinical pharmacist has been suggested, however this has received both positive and 
negative opinions to its proposed implementation.
30
 It was also mentioned by respondent PM 2 that 
clinical pharmacists need not be involved with every patient, and that the perceived pharmacist 
workload could be addressed by up-skilling nursing staff. Working in collaboration with nurses the 
clinical pharmacist work can be targeted to patients at greater risk of medication-related problems 
while still providing some degree of medication therapy service and counselling to all patients within 
the hospital. 
 
Hawthorne and Anderson conducted a systematic review study of the global pharmacy workforce, and 
identified the most common responses to the ever-increasing demand for pharmacists as the 
“increased use of technology, expansion in the number and roles of pharmacy technicians and 
increased numbers of pharmacy graduates”.
35
 In the 2015 ASHP national survey it was found that 
only 18.2% of the pharmacists’ time was spent on drug distribution, a task taking up 77.5% of 
pharmacy technicians’ time.
24
 The expanded use of pharmacy technicians has been widely accepted in 
high-income countries in order to enhance patient-oriented pharmacy services by reducing the need 




The norm in US hospital pharmacies is a technician:pharmacist ratio of 2:1.
47
 In South Africa, 
pharmacy support staff primarily consists of pharmacist’s assistants, either qualified at the basic or 
post-basic level. Currently there are just fewer than 19 000 pharmacist’s assistants registered with the 
SAPC, including those still in training.
20
 The quantitative survey revealed that there was a median of 6 
pharmacy support staff per hospital with 48% of respondents working in hospitals with 7 or more 
pharmacy support staff. However, this might have included clerical staff employed in the pharmacy 
who are not registered with the Pharmacy Council, even though the questionnaire specifically asked 
about pharmaceutically-trained staff. Training for pharmacy technicians in South Africa has recently 
begun. However there is not yet a separate register for pharmacy technicians and they are currently 
required to perform the duties of pharmacist’s assistants (post basic).
44,46




and recognition of the pharmacy technician’s role in the private health care sector in South Africa are 
needed to determine their future role in aiding clinical pharmacy progression. 
     
5.3 Technology to aid clinical pharmacy development  
 
The use of automated dispensing units was mentioned by multiple respondents as a method for 
overcoming barriers to clinical pharmacy service progression due to lack of human and other 
resources. Respondent PM 5 stated: “Probably one of the only other ways forward is when you start 
automating. Looking at a cost effective way of staffing and resourcing, probably automated 
dispensers are the only way to go.” Survey respondents agreed that the use of automated dispensing 
units and pharmacy technicians would be beneficial for clinical pharmacy service development. The 
2014 ASHP national survey showed that 97% of all US hospitals that responded have automated 
dispensing cabinets incorporated in the hospitals medication distribution systems.
23
 The use of 
automated dispensing environments has helped pharmacists to dispense medication more efficiently. 
However, when it comes to prescription management and monitoring, a reduction in pharmacist 
numbers and hours has not yet been seen.
47
     
 
In terms of technology advances focused on medication safety in US hospitals, the ASHP national 
survey revealed that 97.5% of all hospitals surveyed used complete or partial electronic health record 
systems, 93.7% incorporated barcode-assisted medication administration and 84.1% of hospitals used 
computerised prescriber-order-entry (CPOE) systems.
24
 Bar-code electronic medication-
administration system (Barcode eMAR) is focused on reducing medication administration errors 
(including timing errors and potential adverse drug events) by making certain that the right patient 
receives the right medication at the right dose and at the right time, based on a medical practitioner’s 
prescription order, but after it has been approved electronically by the pharmacist.
71
 South African 
private hospitals have incorporated electronic patient medication records and medication labelling is 
computerised, however computerised medical practitioner prescribing software is not common and 
paper-based medication ordering or prescribing is more commonly used.
14
 Computerised patient 
medication records in South African private hospitals are geared largely to billing purposes and are 
not fully integrated with other electronic patient-related systems in the hospital, such as those for 
laboratory or radiological data or for the recording of clinical and nursing service provision.
14,72
 There 
is also a need for integration of this type of electronic patient-related medication recording platform 
across individual institutions, both within the group and across different private hospital groups, to 
build comprehensive patient medical profiles that can be accessed at different points of care. Investing 
in CPOE and Barcode eMAR type systems will extend the approach to ensuring medication safety 




The continuous recording of prescribing and administration data will also aid in drawing attention to 
potential areas where processes could be improved, often not an easily achievable task using labour 
intensive paper-based systems. 
 
Using software, as mentioned by respondent PM 5, has helped to get hospital pharmacists to approach 
a clinical environment with purpose and perform duties outside of dispensing. A key example in the 
South African setting has been the investment by one of the private hospital groups in the Bluebird 
software suite (http://www.intelms.com/ams.html),73 a prospective antimicrobial auditing tool that is 
able to build a patient electronic medical record by extracting information on antimicrobials used and 
laboratory data received in real time. This software allows the clinical pharmacist to audit target 
antimicrobials, access laboratory information and record interventions. The growing focus in private 
hospitals in South Africa, following global concern, has been on antimicrobial stewardship and this is 




5.4 The need for Governmental and Hospital support 
 
A major barrier to clinical pharmacy progression in South African hospitals cited by respondents is 
the lack of registration of clinical pharmacy as a speciality category and the need for the SAPC to 
recognise, establish and clearly define the role of the clinical pharmacist. As respondent PM 7 noted: 
“Government needs to define the roles of clinical pharmacists clearly”. The inclusion of the clinical 
pharmacist as a speciality category was proposed by the SAPC in December 2014 but has not yet been 
finalised.
42
 Clinical pharmacist registration was agreed with by 70.8% of survey respondents as a vital 
step in clinical pharmacy progression in the country. Along with defining the role of the clinical 
pharmacist, it is also important to establish the responsibilities attributed to this new role. Survey 
respondents agreed that an increased responsibility attributed to the clinical pharmacist for the 
patient’s clinical outcome will enhance clinical pharmacy services.  
 
Once the role has been established, a national clinical pharmacy programme must be implemented for 
both public and private sectors. It was mentioned by respondent PM 6 that for clinical pharmacy to 
progress, it should be nationally driven and not divided as each hospital group pursues their own idea 
of what clinical pharmacy should entail. Respondent R7 agreed: “Clinical pharmacists are spread 
between different private and public hospital groups with different visions for clinical pharmacy.” 
 
A nationally implemented clinical pharmacy programme could overcome the perceived barrier of 
uncertainty about the role of the clinical pharmacist as viewed by other health care professionals and 




practitioners and nurses do not see clinical pharmacists as contributing to patient outcomes but merely 
as dispensers of medication. The lack of recognition of the role of and need for the clinical 
pharmacists is also seen in other low- and middle-income countries.
32
 A qualitative study conducted 
by Morecroft et al. in three National Health Service (NHS) general hospitals in England showed the 
lack of inpatients’ awareness of the hospital pharmacist’s contributory role in patient care.
74
 These 
authors conducted semi-structured interviews with 74 inpatients from the acute medical wards and 
found that 57% of all participants had no expectation of seeing a pharmacist at ward level during their 
stay and were actually surprised to see pharmacists outside of their traditional dispensing role.
74
 It was 
found, however, that 65% of patients felt that the pharmacist, compared to other health care 
professionals, was actually more approachable with regard to mediation-related issues. However, due 
to a lack of insight into the clinical role of the pharmacist, outside of medication distribution and 
dispensing, the patients’ expectation of the pharmacist for any greater contribution to patient care was 
not evident.
74
 Added to the need for continuous promotion of clinical pharmacy services within the 
community, Morecroft et al. mentioned that pharmacists simply need to introduce themselves at the 
bedside and provide a leaflet indicating their role with a means of being contacted, to aid further 
development of the clinical pharmacist services in patient care.
74
 Lack of patient understanding of the 
role of the clinical pharmacist was also identified as a barrier for clinical pharmacy progression by 
Penm et al.
12
 Patient education and counselling through increased pharmacist exposure to the ward 
environment will aid in overcoming this barrier to clinical pharmacy progression. This type of 
remedial strategy was also suggested by Penm et al., who noted that regular education and counselling 
of the patient’s medication would aid in their understanding and acceptance of the role and 
responsibilities of the clinical pharmacist.
12
 Respondent PM 5 mentioned that the role of the clinical 
pharmacist will eventually be understood by patients through the education of nurses and medical 
practitioners, who would then reinforce this view with their patients.    
 
Governmental and hospital management support are critical for the progression of clinical pharmacy 
services. Survey respondents stated that influence and support from hospital management as well as 
from other health care professionals is important. As clinical pharmacy is in its infancy stage in South 
Africa, the invested benefits within hospitals on patient clinical outcome will not be seen 
immediately, but with the introduction of antibiotic stewardship programmes in private hospital, the 
benefits of hospital pharmacists providing more clinical, non-distributive services are being noticed.
40
 
The need for governmental and hospital administrative support for clinical pharmacy progression was 
also seen in Chinese hospitals.
12
 Penm et al. suggested that clinical pharmacists should promote 
clinical pharmacy services in China, together with hospital administration, and that the clinical 
pharmacist should be actively involved in conducting research to improve systems. These authors also 






 Motivation, incentive and lack of clear career path for clinical pharmacists, 
as mentioned by respondents, also hinder clinical pharmacy progression. Retaining pharmacists who 
pursue further qualifications and training is a challenge. 
 
Respondents mentioned that one of the other problems facing clinical pharmacy progression is the 
fact that, in the South African private hospital sector, medical practitioners are not under the employ 
of the hospital and practise in their own private capacity. Respondents mentioned that, due to this 
arrangement, medical practitioners tend to follow their own protocols and guidelines, can prescribe 
whatever they want without restriction, and take full accountability for patient’s clinical outcomes, 
thus reducing the opportunities for a multidisciplinary approach to patient care. Internationally, a 
recent push by US hospitals in employing primary care physicians has been seen.
75
 The Medical 
Group Management Association showed a nearly 75% increase in the number of active doctors 
employed by US hospitals since 2000. The move to hospital employment in the US is seen more with 
young practitioners, who value the more structured work-life balance, lifestyle flexibility and 
administrative simplicity seen in hospital employment over a higher income incentive.
75
 The process 
of implementation of National Health Insurance (NHI) within South Africa might be seen as a way to 
entrench similar trends, but is expected to take up to 14 years to complete.
14
 The approach to and 
movement of medical practitioners within the country with regards to hospital employment will be of 
interest when this system is implemented nationally.            
 
It is important to approach and build therapeutic relationships with medical practitioners and the use 
of Drug and Therapeutics Committee (DTC) and Antibiotic Stewardship Committee (ASC) meetings 
should be encouraged in private hospitals. It was noticed that 40.6% of survey respondents either did 
not have a DTC at present or one that met regularly within their hospital. Respondents did mention 
that, due to medical practitioners not being employed by the hospital, it was a challenge to get their 
attendance at such meetings. The DTC is a multidisciplinary group that is involved with formulary 
management, medication use evaluation, adverse drug reaction monitoring and reporting and issues of 
medication safety.
76
 Respondents agreed that multidisciplinary ward rounds should also be 
encouraged within hospitals to aid in building therapeutic relationships and promoting collaborative 







5.5 Basel Statements as a tool to monitor clinical pharmacy progress  
 
The FIP Basel Statements on the Future of Hospital Pharmacy, developed in August 2008 and revised 
in September 2014, were designed to reflect the ideal vision of hospital pharmacy practice in a 
hospital pharmacy environment.
7,8
 Multiple independent studies, in the Western Pacific region in 
particular, have been conducted to assess the current state of pharmacy practice, using the six aspects 
of hospital pharmacy practice as set out by these Statements.
12,55,56
 These types of studies have not yet 
been conducted to assess the level of hospital pharmacy practice in South Africa. They are of value as 
they create a benchmark to assess pharmacy practice within hospitals for comparison and 




The Basel Statements BS26 – BS32, dealing with “influence on prescribing”,
7
 were successfully used 
as an aid to assess and compare multiple private hospitals within the same private hospital group with 
regard to their level of clinical pharmacy progression and the barriers experienced. Adaptation of the 
Basel Statements for use in the South African hospital practice and consideration of relevance of each 
Statement should be considered, as has been successfully done by the European Association of 
Hospital Pharmacists (EAHP).
57,77
 As clinical pharmacy services progress in South Africa, the 
monitoring and surveying of these processes and systems through independent studies in both public 
and private hospitals will be beneficial, in order to observe potential barriers and suggest further 
methods to overcome them. 
 
5.6 Limitations and remedial steps 
 
The response rate for the qualitative phase of the study was poor and the planned minimum target was 
not achieved. A total of 7 respondents were included, out of 44 managers in the group, representing a 
response rate of 15.9%. In order to bolster the response, a regional clinical pharmacist was included in 
the sample group. The initial response deadline was also extended, and 7 selected pharmacy managers 
were approached directly, of which 3 responded and were included in the study. More time could 
have been dedicated to qualitative data collection during this phase and, if encouragement from the 
private hospital group head office had been received, a larger sample size could have been attained. 
However, saturation was deemed to have been achieved, as no new issues or themes appeared to 
emerge after the initial 7 interviews. That said, as the sample size for the qualitative study was small, 
and selected pharmacy managers had to be approached directly, it is possible that the views and 
attitudes of this group do not fully represent that of the entire population of pharmacy managers in the 
group. The non-responders may differ systematically from those who chose to respond, either in being 




progression of clinical pharmacy in the South African private hospital sector. Nonetheless, it has been 




The quantitative phase involved data collection through the use of SurveyMonkey, an online survey 
tool. In order to ensure that respondent confidentiality was maintained, all responses were completely 
anonymised and the email addresses of respondents was not captured. It was therefore possible a 
respondent could complete the survey more than once. An attempt was made to avoid this eventuality, 
as each reminder email that was sent out included specific instructions to not complete the survey a 
second time. It was also possible that multiple respondents from the same hospital could complete the 
survey, providing different (and perhaps inaccurate) hospital demographic details. Corporate data that 
was obtained to create the sample frame was thus used to determine actual hospital demographics for 
the group. The average hospital bed size within the private hospital group is 185 beds with the median 
hospital size being in the band of 100-199 beds (IQR: 100-299). From the survey data, the median 
was in the 200-299 bed band. The total number of pharmacists and pharmacy managers employed by 
the hospital group in January 2016, during data collection, was 258. Of these, only 243 could be 
included in the sample frame, due to invalid or unobtainable email addresses. Reasons for such invalid 
or unobtainable email addresses might have been the presence of new staff members who had not yet 
been issued with a corporate email address or the presence on the list of recently resigned staff 
members. The median number of pharmacists per hospital obtained from corporate records was 4 
(IQR: 3-6), compared with the median of 6 pharmacists per hospital reported from the survey data. In 
hospitals of 100-199 beds the number of pharmacists employed varied from 3 to 5. In hospitals with 
200-299 beds, corporate records showed that 7 or more pharmacists were commonly employed. The 
data obtained from the study was therefore closely related to the corporate data obtained and therefore 
the sample was considered a good reflection of the population. However, it might have been that 
respondents were more likely to be from larger hospitals rather than smaller, and hence more likely to 
be in a position to be exposed to more extensive clinical pharmacy services, including the 




The perceived barriers to clinical pharmacy progression in the South African private hospital sector, 
as acknowledged by pharmacy managers and hospital pharmacists, need to be exposed in order to 
plan and implement remedial action. 
 




 the educational needs of the clinical pharmacist and the lack of a recognized, structured 
undergraduate or post-graduate clinical pharmacy degree for specialist registration in South 
Africa; 
 lack of confidence of the clinical pharmacist in his/her own clinical knowledge; 
 the lack of registration of clinical pharmacy as a speciality category by the SAPC; 
 the lack of established, clear defined roles and responsibilities of the clinical pharmacist in the 
hospital setting; 
 lack of recognition of the role and support of the clinical pharmacist in patient care from 
hospital administrators as well as from the prescriber’s, nurse’s and patient’s point of view; 
 shortage of clinical pharmacists and the need for restructuring of staffing structures; 
 the need for a clearly defined and established role for pharmacy technicians in private hospital 
settings; and 
 the need for investment in technology, in order to compensate for resource limitations and 
specifically for medication safety purposes. 
 
Support for clinical pharmacy progression at individual hospital management as well as from hospital 
group management level is essential for the progression of clinical pharmacy, if it is to become the 
primary role of the hospital pharmacist. Concluding remarks and recommendations on how to 
overcome these perceived barriers in order to advance its progression are provided in the following 


















Chapter VI: Conclusions and Recommendations 
 
Clinical pharmacy and the provision of services focused more on the pharmaceutical care of the 
patient, is slowly progressing within South African private hospitals. This “new” role is one that will 
further promote and add value to the pharmacist’s standing as a member of the multidisciplinary 
therapeutic team in contributing to better patient clinical outcomes.   There are, however, a number of 
barriers that are impeding further progress of this role both internally (such as the lack of self-
confidence and willingness of the hospital pharmacist to adapt to this change) and externally (which 
are often factors outside of the pharmacist’s control). 
 
External or structural barriers to clinical pharmacy progression explored within this study were those 
of governmental and hospital influence, pharmacy operational factors and the further clinical 
educational requirements of the hospital pharmacist. Multiple perceived barriers were identified 
concerning governmental and hospital influence, but most significant was the lack of a recognised 
clinical pharmacist specialist registration category in South Africa, coupled to a clearly defined scope 
of practice. The exact role of the clinical pharmacist will remain unclear to pharmacists as well as 
other health care professionals and patients until the registration is finalised and promoted in society 
and the curricula of nurses and medical practitioners. Once finalised, implementation of a national 
clinical pharmacy programme accompanied by patient education in the public and private sector, will 
serve to promote the role and responsibility of the clinical pharmacist. Until then, governmental and 
hospital administrative support and recognition of clinical pharmacy is vital for the progression of this 
service. Individual hospitals should create opportunities for pharmacists to provide a clinical service 
and start to establish therapeutic relationships with other health care providers through the 
establishment and maintenance of multidisciplinary groups like DTC and ASC meetings. This will aid 
the implementation of the clinical pharmacy service, once registration with SAPC is eventually 
finalised. 
 
Further barriers to clinical pharmacy progression identified were related to resource allocation in 
relation to staffing numbers, staff structure and time available to provide clinical services. Pharmacists 
in South Africa are a scarce skill occupation, so the availability of extra pharmacists per hospital or 
the use of current employees to provide additional clinical services over and above priority services, 
like medication distribution and dispensing, was identified as a challenge. The staff structure needs to 
adapt to include this additional role of the pharmacist. The use of pharmacy support staff, like 
pharmacy technicians, to provide the “foundation of the pharmacy’s distributive function”
25
 is needed 
in South African hospitals as is currently being performed by pharmacy technicians in the US and 




to start initiating and maintaining clinical services by providing personnel capable of supporting stable 
drug distributive and dispensing functions, currently occupying most of the hospital pharmacist’s 
time. Therefore, there is a need for SAPC to further structure the role and responsibilities of pharmacy 
technicians in South Africa, more specifically in the private hospital sector, where their distinctive 
role compared to pharmacist’s assistants (post basic) is unclear.  
 
Technology, and in particular automated dispensing units, should be explored in private health care 
hospitals to strengthen the medication distributive system, especially in settings with limited human 
resources. Software applications (like Bluebird) have helped to empower the pharmacist to perform 
more clinical functions in the hospital, but there is a need to explore these applications further in order 
to build fully integrated electronic health recording systems, looking at all health-related data and not 
only antibiotic stewardship information.   
 
Education and the pharmacist’s lack of clinical knowledge was identified as a major barrier to clinical 
pharmacy progression. This was largely attributed to the lack of further formal clinical training as an 
entry-level requirement in the hospital setting. It was also reported that pharmacists are not taking 
personal responsibility for their own clinical knowledge. However, there is a need to restructure and 
standardise the current undergraduate degree to be more clinically-focused and create qualified 
pharmacists that can enter the hospital sector with the required skill set. A post-graduate degree option 
should also be made available, for those qualified pharmacists wanting to register as a clinical 
pharmacist, when the speciality register is finalised. Therefore, the implementation of a restructured, 
clinically-focused undergraduate pharmacy programme requires the co-implementation of a bridging 
post-graduate degree that acknowledges prior learning. The bridging options should include the 
possibility of part-time study, due to financial constraints and family obligations faced by current 
qualified full-time employed hospital pharmacists. The pharmacist’s poor self-confidence and attitude 
to change is largely dependent on the lack of clinical knowledge and training received, as well as a 
lack of a clear and shared understanding of the clinical pharmacist’s role.  
 
The future of clinical pharmacy in South Africa will greatly benefit from the use of the Basel 
Statements as a tool to initiate studies in monitoring its progression and identifying its barriers. 
Adaptation of the Basel Statements to be more relevant to the South African setting will allow 
hospitals pharmacists to create a benchmark to which local hospitals in both the public and private 
sector could be held to account. In that way, the level of clinical pharmacy practice in their hospital 
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Informed consent document for semi-structured interview sessions 
Informed Consent 
I ______________________ have been informed about the study entitled “Clinical pharmacy 
services in a South African private hospital group, and the factors hindering their progress” by 
Kenneth van der Walt (the researcher). 
 
I understand the purpose and procedures of the study. 
I understand that the interview may be recorded and that anonymous quoting may be used in 
reporting of this interview. 
I have been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any time 
without penalty. 
 
If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher at 021 000 0000 or via email at kenneth.vanderwalt@nnnnnnnn.co.za. 
If I have any questions or concerns about my rights as a study participant, or if I am concerned about 
an aspect of the study or the researcher then I may contact: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
____________________      ____________________ 





Semi-structured interview questionnaire 
Clinical pharmacy services in a South African private hospital group, and the factors 
hindering their progress.  
The Basel Statements were set out by the Hospital Pharmacy Section of the International Pharmaceutical 
Federation in August 2008 and are a list of 75 statements developed to reflect the ideal vision of pharmacy 
practice in a hospital pharmacy environment. Six aspects describing the full scope of the profession within the 
hospital setting were incorporated within these statements.  
Clinical pharmacy services, being that of a provision of pharmaceutical care to the patient outside of normal 




26 Hospitals should utilize a medicine formulary system (local, regional, and/or national) linked to 
standard treatment guidelines, protocols, and treatment pathways based on the best available 
evidence. 
27 Hospital pharmacists should be members of pharmacy and therapeutics committees to oversee all 
medicines management policies and procedures, including those related to off-label use and 
investigational medicines. 
28 Hospital pharmacists should have a key role in educating prescribers at all levels of training on the 
access to and evidence for optimal and appropriate use of medicines, including the required 
monitoring parameters and subsequent prescribing adjustments. 
29 Hospital pharmacists should be involved in all patient care areas to prospectively influence 
collaborative therapeutic decision-making. 
30 Hospital pharmacists should be an integral part of all patient rounds to assist with therapeutic 
decision-making and advise on clinical pharmacy and patient safety issues. 
31 Hospital pharmacists should provide continuity of care by transferring patient medicines information 
as patients move between sectors of care. 
32 Postgraduate clinical courses should be developed to prepare hospital pharmacists for collaborative 
prescribing of medicines, including instruction in legal and professional accountability; this role of 
hospital pharmacists should be promoted in the curricula of other health professionals. 
Interview questions 
1. Can you briefly describe yourself in terms of age, gender, educational background and years of 
managerial and hospital pharmacy experience? 
2. Going through each statement, to what extent are these processes implemented in your hospital?  
3. What factors are challenging the implementation of these processes in your hospital? 
4. What strategies could be used to approach and overcome these challenges in your hospital? 
5. What are your feelings, views or attitudes towards the level of clinical pharmacy in South Africa? 
                                                          







Survey questionnaire administered through SurveyMonkey
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